CN107469085A

CN107469085A - Treat method, composition and the kit of pain and itch

Info

Publication number: CN107469085A
Application number: CN201710850341.1A
Authority: CN
Inventors: B.P.比恩; C.J.伍尔夫
Original assignee: Harvard College; General Hospital Corp
Current assignee: Harvard College; General Hospital Corp
Priority date: 2006-11-20
Filing date: 2007-11-19
Publication date: 2017-12-15
Also published as: CN101610789A

Abstract

It is it is a feature of the present invention that a kind of by the way that cell is contacted to suppress the method for one or more of cell voltage gated ion channel voltage-gated ion channel with following material：(i) the first compound, it activates the passage being present on nociceptor and/or pruriceptors and forms acceptor；(ii) second compound, it suppresses the ion channel when putting on the inner surface of one or more voltage-gated ion channels, but the passage is not suppressed when putting on the outer surface of the passage substantially, wherein, when the acceptor is activated, the second compound can form acceptor by the passage and enter nociceptor or pruriceptors.The present invention is further characterized in that the quaternary ammonium derivative or other permanently charged or instantaneous powered derivatives of compound, the compound suppresses the ion channel when putting on the inner surface of one or more voltage-gated ion channels, but does not suppress the passage substantially when putting on the outer surface of the passage.

Description

Treat method, composition and the kit of pain and itch

The application be Application No. 201410034926.2, the applying date be on November 19th, 2007, it is entitled " treatment The divisional application of the Chinese patent application of the method for pain and itch, composition and kit ".

Technical field

The present invention relates to pass through small molecular weight drugs molecule selective depression pain-and gargalesthesia (itch) sensory neuron (sensing neuron) (nociceptor (nociceptors) and pruriceptors (pruriceptors)), while will be right Method, composition and the kit that the influence of non-pain (non-pain) sensory neuron or other cell types minimizes.Root According to the inventive method, small hydrophilic medicament molecule is present in pain-and gargalesthesia-sensory neuron but at it by entering through Less or not existing acceptor in his types of neurons or other types of tissue be present and enter pain-sensory neuron Cellular compartment in.

Background technology

Local anesthetic (such as lidocaine and Articaine) is by suppressing the voltage-dependent in neuron (voltage-dependent) sodium channel and play a role.Simultaneously thus block all neurons in these narcotic blockade sodium channels Excitability, rather than just sensation of pain neuron (nociceptor).Therefore, although part or the purpose of regional anesthesia are Retardance nociceptor in signal transmission to prevent relieve the pain pain, but using local anesthetic can also produce it is undesirable or bad (deletrious) influence, such as caused by the retardance of Low-threshold Pressure and thigmoreceptor total numbness, by motion aixs cylinder Movement defect and other complication as caused by from the retardance of principal fiber caused by the retardance of (motor axons).Local fiber crops Liquor-saturated medicine is the molecule of relative hydrophobicity, enters their retardances on sodium channel by diffusing into or spreading through cell membrane Site.Permanently charged (Permanently-charged) derivative (such as QX-314, the season of lidocaine of these compounds Nitrogen (quaternary nitrogen) derivative) impermeable cell membrane, when being applied to neurilemmal outer surface to neuron Sodium channel is without influence, but if in some way (such as by being learnt for carrying out full cellular electrophysiologicalsensor to the neuron of separation The micropipette of record) be introduced into cell interior then can block sodium channels.Sensation of pain neuron by pain heat or Capsaicine (stimulating component in capsicum) is activated and express in terms of (in most cases) TRPV1 receptor/channels and other classes The neuron of type is different.The selective expression in polytype sensation of pain and itch feel (pruriceptors) neuron Other types of acceptor includes but is not limited to TRPA1, TRPM8 and P2X (2/3) acceptor.

Neuropathic pain, inflammatory pain and nociception (nociceptive) pain are in teiology, pathologic, physiologic Learn, be different in terms of diagnosis and treatment.Periphery in response to strong or nocuity stimulant to specific subgroup (subset) The activation of sensory neuron (nociceptor) and there is nociceptive pain.This pain is usually acute and self limitation Property, play protectiveness biological function by alerting possible or ongoing histologic lesion.Generally this pain limit In part (well-localized).The example of nociceptive pain includes but is not limited to wound (traumatic) or operation Pain caused by pain, pain of childbirth, strain, fracture, burn, shock pain (bumps), contusion (bruises), injection (injections), pain (skin caused by pain caused by dental procedure (dental procedures), skin biopsy Biopsies) and obstruction caused by pain (obstructions).

Inflammatory pain is the pain occurred when tissue damage or inflammation be present, including postoperative pain, post-traumatic pain, pass Scorching (the rheumatoid or osteoarthritis) pain of section and the pain related to the damage of joint, muscle and tendon (such as it is axial descend waist (axial low back pain) bitterly.

Neuropathic pain is a kind of common chronic, non-malignant pain, and it is by periphery or central nervous system Caused by damage or dysfunction, this pain does not have protectiveness biological function.It is estimated that this pain surpasses in U.S. influence Cross 1,600,000 people.Neuropathic pain has a variety of different teiology, and can with due to the fact that and this pain occurs, example Such as wound, operation, disc herniation, spinal cord injury, diabetes, herpes zoster infection, HIV/AIDS, advanced cancer, amputation (including mastectomy), carpal tunnel syndrome, long-term alcohol (chronic alcohol use), exposed to radiation, it is also possible to (unintended) unintentionally of neurotoxic healing potion (such as medicine and chemotherapeutics of some anti-HIVs) is secondary to be made With.

With nociceptive pain on the contrary, neuropathic pain is frequently described as having " burning sensation in nature (burning) ", " electric-shock feeling (electric) ", " tingle " or " tingling sensation (shooting) ".Its feature is often chronic Allodynia (being defined as the pain as caused by the stimulation (such as touching) for not causing pain reaction generally) and hyperalgia are (fixed Justice is the sensitiveness increase to normal pain stimulation), also sustainable several months or number after the recovery from illness of any damaged tissues outward appearance Year.

Due to many reasons, pain can occur in cancer patient：Inflammation, compressing (compression), invasion and attack, transfer Property is diffused into bone or other tissues.

There are some illnesss, pain occurs in the case of no noxious stimulus, tissue damage or nervous system damage, this A little illnesss are referred to as dysfunction (dysfunctional) pain, and including but not limited to fibromyalgia, pressure-type headache, intestines are easy Swash disorder (irritable bowel disorders) and erythromelalgia.

Antimigraine is the sensation fibre with dominating meninx movable (innervating the meninges of the brain) The related headache of dimension activation.

Gargalesthesia (itch) is a kind of dermatological disorders, its can be topically or systemically, can with skin lesion (fash, Atopic eczema, wheal) it is related.Gargalesthesia includes but is not limited to along with various disease conditions, stress, anxiety, sunlight ultraviolet radioactive, It is metabolized with endocrine disturbance (for example, liver or kidney trouble, hyperthyroidism), cancer (such as lymthoma), to medicine Or reaction, parasite and the fungal infection of food, allergic reaction, hematologic disease (such as polycythemia vera) and skin Learn illness.Gargalesthesia is mediated by a subgroup minor diameter Primary Sensory Neuron (pruriceptors), and these neurons have wound Many features of evil receptor neuron, including but not limited to express TRPV1 passages.Some gargalesthesia media (mediators)- Such as eicosanoids, histamine, bradykinin, ATP and various neurotrophins have endogenous Vanillin (endovanilloid) function.Local application capsaicine suppresses the gargalesthesia of histamine induction.Therefore, as nociceptor, scabies Gargalesthesia receiver is the suitable targets of this method for delivering ion channel blocking agent.

Although a variety of therapies for pain and gargalesthesia are carried out, it is still desirable to medicament in addition.

The content of the invention

In a first aspect, the invention is characterized in that suffered from by giving the compound of patient first and the treatment of optional second compound Pain and gargalesthesia (itch) (such as neuropathic pain, inflammatory pain, nociceptive pain, idiopathic pain, the cancer of person Pain, antimigraine, dysfunction pain or operational pain (procedural pain) (such as by dental procedure, injection, Pain caused by fracture fixation (setting fractures), biopsy)) and itch method, first compound applies Suppress the ion channel when inner surface (the internal face) of one or more voltage-gated ion channels, but apply Do not suppress the passage substantially when being added on outer surface (the external face) of the passage, wherein when acceptor is activated, First compound can enter neuron by membrane-bound receptor/ion channel；The second compound activation described first is changed The acceptor that compound can pass through.In some embodiments, second compound activation is selected from TRPV1, P2X (2/3), TRPA1 and TRPM8 Acceptor, first compound can pass through these acceptors.Any standard pain can be used or disease index of itching (such as is described herein Those) determine the treatment of pain or disease of itching, or can be evaluated based on the subjective pain or gargalesthesia of patient to determine pain or itch The treatment of disease.If reported pain reduces or the reaction reduction of the stimulation to that can cause pain and gargalesthesia reduction, then it is assumed that suffers from Person has obtained " treating ".In some embodiments, it is desirable to give second compound to ensure acceptor (such as TRPV1, P2X (2/ 3), TRPA1 and/or TRPM8 acceptors) it is activated, so as to allow the first compound to enter.In other embodiment, due to acceptor (such as TRPV1, P2X (2/3), TRPA1 and/or TRPM8 acceptors) has been activated, and does not give second compound.Therefore, first Compound only enters the neuron of the acceptor with endogenous stimulation.In other embodiment, acceptor (such as TRPV1, P2X (2/ 3), TRPA1 and/or TRPM8 acceptors) physiological status that activates these acceptors by sensing is activated, so as to allowing the first change Compound enters.

If desired, two or more changes of activation TRPV1, P2X (2/3), TRPA1 and/or TRPM8 acceptors can be used Compound, it is possible to use suppress two or more compounds of one or more voltage-gated ion channels.It is desirable that first Compound (one or more) and second compound (one or more) can (be spaced) in 4 hours each other, in 2 hours, 1 hour It is interior, give patient in 30 minutes or in 15 minutes, or be substantially simultaneously administered.It is importantly, each in both compounds Kind can be administered first.Therefore, in a kind of embodiment, activation TRPV1, P2X (2/3), TRPA1 and/or TRPM8 are given first One or more compounds of acceptor, and in another embodiment, give first one or more valtage-gated when putting on Property ion channel inner surface when suppress the passage, but do not suppress described logical when putting on the outer surface of the passage substantially One or more compounds in road.These compounds can co-formulation enter in single composition or can prepare respectively.Example can be passed through Each compound is given as follows：Oral administration, parenteral, intravenous administration, intramuscular administration, rectally, skin (cutaneous) administration, subcutaneous administration, local administration, cutaneous penetration, sublingual administration, nose administration, vagina administration, intrathecal give Medicine, epidural administration or dosing eyes, or by injecting, sucking or directly contacted with schneiderian membrane or oral mucosa.

The activator of TRPV1 acceptors includes but is not limited to capsaicine (capsaicin), eugenol, arvanil (N- peanuts Tetraene acyl vanilla amine (arachidonoylvanillamine)), anandamide (anandamide), 2- amino ethoxies Base diphenyl-borinic acids ester (aminoethoxydiphenyl borate) (2APB), AM404, RTX (resiniferatoxin), phorbol 12-phenylacetic acid ester 13- acetic acid esters 20- homovanillic acid esters (phorbol 12- Phenylacetate 13-acetate20-homovanillate) (PPAHV), Olvanil (NE 19550), OLDA (N- oleoyls Dopamine), N- arachidonic acid base dopamines (arachidonyldopamine) (NADA), 6'- iodo RTXs (iodoresiniferatoxin) (6'-IRTX), C18N- acyl ethanol amines (acylethanolamines), LOX spread out Biological such as 12- hydroperoxidations arachidonic acid (hydroperoxyeicosatetraenoic acid), the Guang ammonia of inhibitor half Acid knot (inhibitor cysteine knot) (ICK) peptide (vanilla toxin (vanillotoxins)), pipering, MSK195 (N- [2- (3,4- dimethyl benzyls -3- (new pentane acyloxy (pivaloyloxy)) propyl group] -2- [4- (2- amino ethoxies) -3- Anisyl] acetamide), JYL79 (N- [2- (3,4- dimethyl benzyls -3- (new pentane acyloxy) propyl group]-N'- (4- hydroxyls -3- Methoxybenzyl) thiocarbamide), hydroxyl-alpha-sanshool (sanshool), 2-APB ester, 10- salad oils (shogaol), oleyl gingerol (oleylgingerol), oleyl salad oil (oleylshogaol) and SU200 (N- (4- T-butylbenzyl)-N'- (4- hydroxyl -3- methoxybenzyls) thiocarbamide).Other activator of TRPV1 acceptors are described in O'Dell etc., Bioorg Med Chem(2007)15:6164-6149 and Sexton etc., FASEB J (2007) 21:In 2695-2703.

The activator of TRPA1 acceptors include but is not limited to cinnamic acid, allyl isothiocyanate, diallyl disulfide, Icilin, cinnamon oil, wintergreen, caryophyllus oil, methacrylaldehyde, hydroxyl-alpha-sanshool, 2-APB ester, 4- Hydroxynonenal (hydroxynonenal), methyl p-hydroxybenzoate, mustard oil and 3'- carbamyl biphenyl -3- basic rings oneself Aminocarbamic acid ester (URB597).Other activator of TRPA1 acceptors are described in Taylor-Clark etc., Mol Pharmacol (2007)PMID:18000030；Macpherson etc., Nature (2007) 445:541-545；With Hill etc., J Biol Chem (2007)282:In 7145-7153.

The activator of P2X acceptors includes but is not limited to ATP, 2- methyl mercapto-ATP, 2' and 3'-O- (4- Benzoylbenzene first Acyl group)-ATP and ATP5'-O- (3- thio triphosphates salt (thiotriphosphate)).

The activator of TRPM8 acceptors includes but is not limited to menthol, icilin, cineole, linalool, geraniol and hydroxyl Citronellal.

In some embodiments, the first compound suppresses voltage gated sodium channels.Such exemplary inhibitor is QX- 314th, QX-222, QX-222, N- octyl group-guanidine, 9-aminoacridine and Pancuronium Bromide (pancuronium).

In other embodiment, the first compound suppresses voltage-gated calcium channel.Such exemplary inhibitor is D- 890 (season methoxyverapamils (quaternary methoxyverapamil)) and CERM11888 (season bepridil (quaternary bepridil))。

In other embodiment, the first compound is the quaternary amine (quarternary amine) selected from following compound Derivative or other powered derivatives：Riluzole, mexiletine (mexilitine), phenytoinum naticum, carbamazepine, procaine, Ah For cacaine, Bupivacaine (bupivicaine), mepivacaine (mepivicaine), tocainide, prilocaine, norpace (disopyramide) (diisopyramide), Bencyclane, quinindium, bretylium tosylate (bretylium), Lifarizine, Lamotrigine, flunarizine And fluspirilene (fluspirilene) (flunarizine).This document describes Exemplary derivatives.

The present invention is further characterized in that quaternary ammonium derivative or other powered derivatives selected from following compound：Li Lu Azoles, mexiletine, phenytoinum naticum, carbamazepine, procaine, Articaine, Bupivacaine, mepivacaine, tocainide, propylamine card Cause, norpace (disopyramide), Bencyclane, quinindium, bretylium tosylate, Lifarizine, Lamotrigine, flunarizine and fluspirilene.

In related fields, the invention is characterized in that pharmaceutical composition, it includes pharmaceutically acceptable excipient and is selected from The quaternary ammonium derivative of following compound or other powered derivatives：Riluzole, mexiletine, phenytoinum naticum, carbamazepine, Proca Cause, Articaine, Bupivacaine, mepivacaine, tocainide, prilocaine, norpace (disopyramide), Bencyclane, quinindium, bromobenzyl Ammonium, Lifarizine, Lamotrigine, flunarizine and fluspirilene.

The present invention is further characterized in that composition, and it is included：(i) the first compound, its activation are selected from TRPV1, P2X (2/ 3), TRPA1 and TRPM8 acceptor；(ii) second compound, it puts on one or more voltage-gated ion channels Do not suppress the passage when suppressing these ion channels during inner surface, but putting on the outer surface of the passage substantially, wherein, When TRPV1, P2X (2/3), TRPA1 and/or TRPM8 acceptors are activated, second compound can be entered by these acceptors aches Pain sensory neuron.In a kind of embodiment, the second compound is active when putting on outer surface or amount of activated reduction, But activity is bigger when putting on inner surface.Can compositions formulated for for example：Oral administration, intravenous administration, intramuscular give Medicine, rectally, percutaneous drug delivery, subcutaneous administration, local administration, cutaneous penetration, sublingual administration, nose administration, vagina administration, sheath Interior administration, epidural administration or dosing eyes, or by injecting, sucking or directly contact administration with schneiderian membrane or oral mucosa. If desired, two or more changes of said composition containing activation TRPV1, P2X (2/3), TRPA1 and/or TRPM8 acceptors Compound, and/or suppress two or more compounds of one or more voltage-gated ion channels.

The present invention is further characterized in that by the way that cell is contacted to suppress one or more of the cell with following material The method of voltage-gated ion channel：(i) the first compound, it is activated selected from TRPV1, P2X (2/3), TRPA1 and TRPM8 Acceptor；(ii) second compound, it suppresses institute when putting on the inner surface of one or more voltage-gated ion channels Do not suppress the passage when stating ion channel, but putting on the outer surface of the passage substantially, wherein, when the acceptor is swashed When living, the second compound can enter sensation of pain neuron by the acceptor.Suitable compound is provided above.

The present invention is further characterized in that identification has the method for treating the compound of pain and gargalesthesia.This method include with Lower step：(a) contact the outer surface of expression TRPV1, TRPA1, TRPM8 and/or P2X (2/3) neuron：(i) first changes Compound, it activates TRPV1, TRPA1, TRPM8 or P2X (2/3) acceptor；(ii) second compound, it puts on one or more Suppress the ion channel during inner surface of individual voltage-gated ion channel, but put on basic during the outer surface of the passage On do not suppress the passage, and (b) determine the second compound whether suppress the voltage-gated in these neurons from Subchannel.The second compound has been accredited as treating pain by suppression of the second compound to voltage-gated ion channel Pain and/or the compound for disease of itching.

These methods, composition and kit may further be used to selectivity retardance expression TRPV, TRPA, TRPM and P2X acceptor Neuronal activity in other types of neurons of different members in family, wherein the first compound is to be present in those types Neuron in specific TRPV, TRPA, TRPM and P2X acceptor activator, second compound is impermeable under normal circumstances Cross the sodium or calcium channel blocker of film.

It should be understood that other acceptors may be present, it allows compound to enter (neuronal cell), the institute if without this receptor Stating compound can not enter.Activate one or more compounds in these acceptors and combine and put on one or more voltage doors Do not suppress described substantially when suppressing the passage during inner surface of control property ion channel but put on the outer surface of the passage The co-administered of one or more compounds of passage is also one aspect of the present invention.

Method, composition and the kit of the present invention can prevent pain or gargalesthesia to be touched or motion control without changing. For example, the patient for receiving epidural administration will not completely lose sensation input.

Term " pain " is using its broader sense herein, refers to all types of pain, including acute and chronic pain, example Such as nociceptive pain, such as body pain (somatic) and visceral pain；Inflammatory pain；Dysfunction pain；Idiopathic Pain；Neuropathic pain, such as pain, antimigraine and cancer pain caused by pain caused by maincenter and periphery.

Term " nociceptive pain " draws for including all destructive stimuluses by threat or actual harm bodily tissue Rise pain, the destructive stimulus include but is not limited to hurt (cut), scratch, fracture, extruding injury (crush injury), Burn etc..The pain receptor (nociceptor) of tissue injury is predominantly located in skin, flesh osseous system or internal organ.

Term " body pain " is used to refer to bone, joint, muscle, skin or pain caused by connective tissue.Usual this kind of pain Pain is limited to part (well-localized).

Term " visceral pain " herein be used for refer to internal organs (such as respiratory apparatus, intestines and stomach and pancreas, the urinary tract and Reproductive organs) caused by pain.Visceral pain includes involving (tumor by the tumour of organ capsule (capsule) Involvement pain caused by).The another type of visceral pain generally as caused by the obstruction of hollow viscus, it is special Levy as interval spastic (cramping) and be less limited to local (poorly localized) pain.Visceral pain can be with Inflammation is related, as in cystitis or reflux esophagitis.

Term inflammatory pain includes the pain related to Active inflammation, the inflammation can by wound, operation, infection and from Body immunological diseases cause.

Term " neuropathic pain " is used to refer to from periphery or central nervous system to by these systems herein The pain of the abnormal processing of the caused sensation input of infringement.

Term " operational pain " is being used to refer to the pain as caused by medical (medical), dentistry or operation technique herein, Wherein described operation has been generally expected to acute injury or related to acute injury.

Term " gargalesthesia ", with its broader sense, refers to all types of locally and systemically (generalized) property, urgency herein Sexual refractoriness property and persistent sensation itched with shouting pain (stinging).Gargalesthesia can be due to hepatopathy, nephrosis or cancer and draw Rise primary, anaphylaxis, metabolic, infectiousness, drug-induced property gargalesthesia." itch (pruritus) " is serious gargalesthesia.

" patient " refers to any animal.In a kind of embodiment, patient is people.Can be used the present invention method, composition and Other animals of kit treatment include but is not limited to non-human primate (for example, monkey, gorilla, chimpanzee), domestic animal (such as horse, pig, goat, rabbit, sheep, ox, alpaca) and companion animals (such as cavy, rat, mouse, lizard, snake, dog, cat, Fish, hamster and bird).

There is the compound described herein for including but is not limited to any pharmaceutically acceptable form for the compound of the present invention, The isomers (such as diastereomer and enantiomer) of the pharmaceutically acceptable form including compound described herein, salt, ester, Acid amides, thioesters, solvate and polymorph, and racemic mixture and pure isomers.

" low molecule amount " refers to less than about 500 dalton.

Term " pharmaceutically acceptable salt " is represented in rational medical judgment scope, is suitable for and people and more low The salt that the tissue of animal is contacted and matched without excessive toxicity, stimulation, allergic reaction etc. and with rational interests/Hazard ratio.Pharmacy Upper acceptable salt is well known in the art.Can during being finally separating and purify of the compounds of this invention it is in situ prepare described in Salt, or by the way that free base function and suitable organic acid reaction are manufactured separately into the salt.Representational acid-addition salts bag Include but be not limited to acetate, adipate, alginate, ascorbate, aspartate, benzene sulfonate, benzoate, sulphur Sour hydrogen salt, borate, butyrate, camphor hydrochlorate (camphorate), camsilate (camphersulfonate), citric acid Salt, cyclopentane propionate, digluconate (digluconate), lauryl sulfate, esilate, fumarate, Portugal Heptose hydrochlorate, glycerophosphate, Hemisulphate (hemisulfate), enanthate (heptonate), caproate, hydrobromate, Hydrochloride, hydriodate, 2- hydroxy-ethanesulfonate salts, isethionate, Lactobionate, lactate, laruate, lauryl Sulfate, malate, maleate, malonate, mesylate (mesylate), mesylate (methanesulfonate), 2- naphthalene sulfonates, nicotinate, nitrate, oleate, oxalates, palmitate, pamoate (pamoate), pectinic acid salt (pectinate), persulfate, 3- phenylpropionic acids salt, phosphate, picrate, neopentanoic acid Salt, propionate, stearate, succinate, sulfate, tartrate, rhodanate, toluene fulfonate, undecylate, valeric acid Salt etc..Representational alkali metal salt or alkali salt include but is not limited to sodium, lithium, potassium, calcium, magnesium etc., and nontoxic ammonium, Quaternary ammonium and amine cation, including but not limited to ammonium, tetramethyl-ammonium, tetraethyl ammonium, methylamine, dimethylamine, trimethylamine, triethylamine, second Amine etc..

In the general description of the compounds of this invention, the number of the atom of particular type is generally with a certain scope in substituent Provide, for example, alkyl or C containing 1-4 carbon atom_1–4Alkyl.When referring to such scope, it is intended that including specifically referring to having The group of each integer atomic in specified range.For example, the alkyl of 1-4 carbon atom includes C₁、C₂、C₃And C₄In each. C_1–12Miscellaneous alkyl is for example including 1-12 carbon atom and one or more hetero atoms.Atom and its can be represented in a similar manner Other numbers of his kind of atom.

Term " alkyl " used herein and prefix " alkane (alk-) " include straight chain and branched group and cyclic group, i.e., Cycloalkyl.Cyclic group can be monocyclic or polycyclic, preferably with 3-6 (including 3 and 6) individual ring carbon atom.It is exemplary Cyclic group includes cyclopropyl, cyclobutyl, cyclopenta and cyclohexyl.

“C_1–4Alkyl " refers to the alkyl of side chain or straight chain with 1-4 carbon atom.C_1–4Alkyl can be substitution or not take Generation.Exemplary substituent includes alkoxy, aryloxy group, sulfydryl, alkylthio group, arylthio, halogen (halide), hydroxyl, fluorine Substituted alkyl, perfluoroalkyl, amino, aminoalkyl, dibasic amino, quaternary ammonium (quaternary amino), hydroxyalkyl, carboxylic Base alkyl and carboxyl.C_1–4Alkyl includes but is not limited to methyl, ethyl, n-propyl, isopropyl, cyclopropyl, Cvclopropvlmethvl, just Butyl, isobutyl group, sec-butyl, the tert-butyl group and cyclobutyl.

“C_2–4Alkenyl " refers to the alkyl of the side chain or straight chain containing one or more double bonds and with 2-4 carbon atom.C_2–4 Alkenyl is optionally including monocyclic or polycyclic, wherein each ring is preferably 3-6 members.C_2–4Alkenyl can be substituted or unsubstituted. Exemplary substituent includes alkoxy, aryloxy group, sulfydryl, alkylthio group, arylthio, halogen, hydroxyl, fluoro-alkyl, perfluor alkane Base, amino, aminoalkyl, dibasic amino, quaternary ammonium, hydroxyalkyl, carboxyalkyl and carboxyl.C_2–4Alkenyl includes but unlimited In vinyl, pi-allyl, 2- cyclopropyl -1- vinyl, 1- acrylic, 1- cyclobutenyls, 2- cyclobutenyls, 3- cyclobutenyls, 2- methyl - 1- acrylic and 2- methyl -2- acrylic.

“C_2–4Alkynyl " refers to containing one or more three keys and the alkyl of the side chain with 2-4 carbon atom or straight chain.C_2–4 Alkynyl is optionally including monocyclic, bicyclic or tricyclic, wherein each ring is preferably 5 or 6 yuan.C_2–4Alkynyl can be substitution or not Substitution.Exemplary substituent include alkoxy, aryloxy group, sulfydryl, alkylthio group, arylthio, halogen, hydroxyl, fluoro-alkyl, Perfluoroalkyl, amino, aminoalkyl, dibasic amino, quaternary ammonium, hydroxyalkyl, carboxyalkyl and carboxyl.C_2–4Alkynyl includes But it is not limited to acetenyl, 1- propinyls, 2-propynyl, 1- butynyls, 2- butynyls and 3- butynyls.

“C_2–6Heterocyclic radical " refers to stable 5-7 unit monocycles or 7-14 membered bicyclic heterocycles, and it is saturation, part insatiable hunger and/or not Saturation (aromatics), formed by 2-6 carbon atom and independently selected from N, O and S 1,2,3 or 4 hetero atom, including wherein appoint Any bicyclic groups what heterocycle defined above merges with phenyl ring.Heterocyclic radical can be substituted or unsubstituted.Exemplary Substituent include alkoxy, aryloxy group, sulfydryl, alkylthio group, arylthio, halogen, hydroxyl, fluoro-alkyl, perfluoroalkyl, amino, Aminoalkyl, dibasic amino, quaternary ammonium, hydroxyalkyl, carboxyalkyl and carboxyl.Nitrogen and sulfur heteroatom are optionally by oxygen Change.Heterocycle can be covalently attached via any hetero atom or carbon atom for producing rock-steady structure, for example, imidazoline basic ring can be in ring Connected at carbon atom position or nitrogen-atoms.Miscellaneous ring nitrogen is optionally quaternized.It is preferred that when S in heterocycle and O atom When sum is more than 1, these hetero atoms do not abut one another.Heterocycle includes but is not limited to 1H- indazoles, 2-Pyrrolidone base, 2H, 6H- 1,5,2- dithiazine base, 2H- pyrrole radicals, 3H- indyls, 4- piperidone bases, 4aH- carbazoles, 4H- quinolizines base, 6H-1,2,5- thiophenes Diazine (thiadiazinyl), acridinyl, azocine base (azocinyl), benzimidazolyl, benzofuranyl, benzothiophene Base (benzothiofuranyl), aisaa benzothiophenyl (benzothiophenyl), benzoxazolyl, benzothiazolyl, benzo three Oxazolyl, benzo tetrazole radical, benzoisoxazole base, benzisothia oxazolyl, benzimidazole ketone group (benzimidazalonyl), carbazole Base, 4aH- carbazyls, b- carbolines base (carbolinyl), chromanyl, benzopyranyl, cinnolines base, decahydroquinoline Base, 2H, 6H-1,5,2- dithiazine base, dihydrofuran simultaneously [2,3-b] tetrahydrofuran, furyl, furazanyl, imidazolidinyl, imidazoles Quinoline base, imidazole radicals, 1H- indazolyls, sub- indyl (indolenyl), indolinyl, indolizine base, indyl, different benzo furan Mutter base (isobenzofuranyl), isochroman base, iso indazolyl, isoindolinyl (isoindolinyl), Isoindolyl (isoindolyl), isoquinolyl, isothiazolyl, isoxazolyls, morpholinyl, 1,5 phthalazinyls, octahydro are different Quinolyl (octahydroisoquinolinyl), oxadiazolyls, 1,2,3- oxadiazolyls, 1,2,4- oxadiazolyls, 1,2,5- Oxadiazolyl, 1,3,4- oxadiazolyls, oxazolidine base, oxazolyl, oxazole alkyl perimidinyl (oxazolidinylperimidinyl), phenanthridinyl, phenanthroline, phenarsazine base, phenazinyl, phenothiazinyl, Phenoxathiinyl, phenoxazine groups, phthalazinyl, piperazinyl, piperidyl, pteridyl (pteridinyl), piperidines Ketone group, 4- piperidone bases, pteridyl, purine radicals, pyranose, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, Bi Ding Bing oxazolyls (pyridooxazole), pyridine-imidazole base, pyridothiazole base, pyridine radicals (pyridinyl), pyridine Base (pyridyl), pyrimidine radicals, pyrrolidinyl, pyrrolinyl, pyrrole radicals, quinazolyl, quinolyl, 4H- quinolizines base, quinoxaline Base, quininuclidinyl, carboline base, tetrahydrofuran base, tetrahydro isoquinolyl, tetrahydric quinoline group, 6H-1,2,5- thiadiazines base, 1,2, 3- thiadiazolyl groups, 1,2,4- thiadiazolyl groups, 1,2,5- thiadiazolyl groups, 1,3,4- thiadiazolyl groups, thianthrene group, thiazolyl, thienyl, Thiophene benzothiazolyl, thiophene fen and oxazolyl, Thienoimidazole base, thiophenyl, triazine radical, 1,2,3- triazolyls, 1,2,4- triazoles Base, 1,2,5- triazolyls, 1,3,4- triazolyls, xanthyl.Preferable 5-10 circle heterocycles include but is not limited to pyridine radicals, pyrimidine Base, triazine radical, furyl, thienyl, thiazolyl, pyrrole radicals, pyrazolyl, imidazole radicals, oxazolyl, isoxazolyls, tetrazole radical, benzene And furyl, benzothienyl, indyl, benzimidazolyl, 1H- indazolyls, oxazole alkyl, isoxazole alkyl, BTA Base, benzoisoxazole base, hydroxyindole base (oxindolyl), benzoxazole quinoline base, quinolyl and isoquinolyl.Preferable 5-6 members Heterocycle includes but is not limited to pyridine radicals, pyrimidine radicals, triazine radical, furyl, thienyl, thiazolyl, pyrrole radicals, piperazinyl, piperidines Base, pyrazolyl, imidazole radicals, oxazolyl, isoxazolyls and tetrazole radical.

“C_6–12Aryl " refers to aryl (such as the benzene with the ring system that is made up of the carbon atom with conjugated pi electron Base).Aryl has 6-12 carbon atom.Aryl is optionally including monocyclic, bicyclic or tricyclic, wherein each ring ideally has 5 Or 6 members.Aryl can be substituted or unsubstituted.Exemplary substituent include alkyl, hydroxyl, alkoxy, aryloxy group, It is sulfydryl, alkylthio group, arylthio, halogen, fluoro-alkyl, carboxyl, hydroxyalkyl, carboxyalkyl, amino, aminoalkyl, mono-substituted Amino, dibasic amino and quaternary ammonium.

“C_7–14Alkaryl " refers to the alkyl substituted by aryl (such as benzyl, phenethyl or 3,4- dichlorophenethyl), and it has There is 7-14 carbon atom.

“C_3–10Alkane heterocyclic radical " refers to the alkyl substituted by heterocyclic radical, and it has 3-10 carbon atom and one or more miscellaneous Atom (such as 3- furyl methyls, 2- furyl methyls, 3- tetrahydrofurans ylmethyl or 2- tetrahydrofurans ylmethyl).

“C_1–7Miscellaneous alkyl " refers to the alkyl of side chain or straight chain, alkenyl or alkynyl group, its have 1-7 carbon atom and 1, 2nd, 3 or 4 hetero atoms independently selected from N, O, S and P.Miscellaneous alkyl include but is not limited to tertiary amine, secondary amine, ether, thioether, acid amides, Thioamides, carbamate, thiocarbamate, hydrazone, imines, di-phosphate ester, phosphoramidate (phosphoramidates), sulfonamides and disulphide.Miscellaneous alkyl is optionally including monocyclic, bicyclic or tricyclic, wherein respectively Ring ideally has 3-6 member.Miscellaneous alkyl can be substituted or unsubstituted.Exemplary substituent includes alkoxy, virtue Epoxide, sulfydryl, alkylthio group, arylthio, halogen, hydroxyl, fluoro-alkyl, perfluoroalkyl, amino, aminoalkyl, dibasic ammonia Base, quaternary ammonium, hydroxyalkyl, hydroxyalkyl, carboxyalkyl and carboxyl.C_1–7The example of miscellaneous alkyl includes but is not limited to methoxy And ethoxyethyl group.

" halogen " refers to bromine, chlorine, iodine or fluorine.

" fluoro-alkyl " refers to the alkyl being replaced by fluorine atoms.

" perfluoroalkyl " refers to the alkyl being only made up of carbon and fluorine atom.

" carboxyalkyl " refer to formula-(R)-COOH chemical part, wherein R is selected from C_1–7Alkyl, C_2–7Alkenyl, C_2–7Alkynes Base, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl, C_3–10Alkane heterocyclic radical or C_1–7Miscellaneous alkyl.

" hydroxy alkyl " refer to formula-(R)-OH chemical part, wherein R is selected from C_1–7Alkyl, C_2–7Alkenyl, C_2–7Alkynyl, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl, C_3–10Alkane heterocyclic radical or C_1–7Miscellaneous alkyl.

" alkoxy " refers to the chemical substituents with formula-OR, and wherein R is selected from C_1–7Alkyl, C_2–7Alkenyl, C_2–7Alkynyl, C_2–6 Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl, C_3–10Alkane heterocyclic radical or C_1–7Miscellaneous alkyl.

" aryloxy group " refers to formula-OR chemical substituents, and wherein R is C_6–12Aryl.

" alkylthio group " refers to formula-SR chemical substituents, and wherein R is selected from C_1–7Alkyl, C_2–7Alkenyl, C_2–7Alkynyl, C_2–6Heterocycle Base, C_6–12Aryl, C_7–14Alkaryl, C_3–10Alkane heterocyclic radical or C_1–7Miscellaneous alkyl.

" arylthio " refers to formula-SR chemical substituents, and wherein R is C_6–12Aryl.

" quaternary ammonium " refers to formula-(R)-N (R ') (R ") (R " ')⁺Chemical substituents, wherein R, R ', R " and R " ' it is each independent Ground is alkyl, alkenyl, alkynyl or aromatic yl group.R can be alkyl, and it is using as the quaternary ammonium nitrogen-atoms of substituent and another portion Divide connection.Nitrogen-atoms N is covalently attached to the four carbon atom of alkyl, miscellaneous alkyl, heteroaryl and/or aromatic yl group, causes nitrogen former One positive charge of band at son.

" live part " refers to be obtained proton and is accordingly changed into positively charged part (such as ammonium, guanidine at physiological ph (guanidinium) or amidine (amidinium)) or include net positive charge form (net formal positive charge) And the part (such as quaternary ammonium) without protonation.The live part can be permanently charged or instantaneous powered.

Used herein and term " parent (parent) " refers to pathway blocking compound, and it can be by being present in parent compound In amine nitrogen atom quaternized or guanylation (guanylation) effect and be modified.The quaternized and change of guanylation Compound is the derivative of parent compound.Guanidine derivative as described herein exists in the form of their uncharged alkali.These Compound can be used as salt (that is, acid-addition salts) to apply, or (protonated through original position in the form of its uncharged alkali and form electro-mechanical part Point) apply.

By following detailed description and claims, other features and advantages of the present invention will be apparent upon.

Brief description of the drawings

Fig. 1 give extracellular QX-314 (5mM) jointly and capsaicine (1 μM) carrys out selective exclusion capsaicine response (capsaicin-responsive) sodium current in DRGs (DRG) sensory neuron.(a) left column：In the small of culture (24 μm) capsaicine-sensitiveness adult's (adult) DRG neurons in, single 5mM QX-314, single 1 μM of capsaicine And be co-administered 5mM QX-314 and 1 μM of capsaicine wash within 10 minutes into (wash-in) to sodium current (by -70 to - The step of 5mV, triggers) influence.Upper column (top panel)：Of short duration (brief) induces using capsaicine in the neuron The inside electric current (keeping voltage -70mV) extended.Right column：Identical serial medicament administration is to big (52 μm) capsaicine-no The influence of the sodium current of sensitive Neurons.(b) the inside electric current of peak value as the function of test pulse, the test pulse exist Compare (■Square), only exist 5mM QX-314 (● circle), only 1 μM of capsaicine (▲ equilateral triangle) and co-administration 5mM Recorded in QX-314 and 1 μM of capsaicine (▼ dels).Symbol shows the examination of the capsaicin-sensitive neurons small to 25 Average value ± the SEM tested.By 20ms Depolarizing steps, i.e., the holding current potential (holding with 5mV increments from -70mV Potential) (change) triggers electric current to test potential scope.(c) capsaicine and QX-314 combination are to peak value sodium current shadow Loud time course.Cylindricality is represented relative to the average value ± SEM (n=25) for compareing normalized peak value sodium current.

QX-314 is co-administered in Fig. 2 and capsaicine blocks nociception sample (nociceptive-like) DRG neurons Excitability.(a) the depolarization current step (250pA, 4ms) for putting on small (23 μm) DRG neurons triggers nociceptor The wide in range action potential of sample, there is prominent deflection (deflection) (arrow) in the decline stage.2 minutes of QX-314 (5mM) are washed Entering does not influence on (the second column).Capsaicine (1 μM) reduces action potential amplitude (third column), and this is probably as shown in fig. 1 Capsaicine the appropriateness of sodium current is reduced and capsaicine caused by the knot of combination that is passivated of the secondary sodium current of unpolarizing Fruit (probably due to a combination ofthe modest reduction of sodium current produced by capsaicin as in Figure 1and inactivation of sodium current secondary to the depolarization produced by capsaicin).Use much bigger stimulating current Injection, the QX-314 and capsaicine of co-administration still completely eliminate the generation of action potential.(b) action potential amplitude is flat Mean value ± SEM (for QX-314, n=25；For capsaicine and capsaicine+QX-314, n=15).

Fig. 3 intraplantar injections capsaicine (10 μ g/10 μ L) connection QX-314 (2%, 10 μ L) causes to machinery (von Frey silks (von Frey filaments)) and hot destructive stimulus extension local anaesthesia.(a) QX-314 is only injected in vola (2%, 10 μ L；Green symbol), only injection of capsaicin (10 μ g/10 μ L；Black symbols) or QX-314 and capsaicine apply together After (red symbols), the paw withdrawal mechanical threshold of the von Frey silks (hairs) in response to increasing intensity.To maximum efficiency time point Show to peak (57g, arrow) unresponsive animal numbers at all.(*=p<0.05, each group n=6).(b) and in (a) Hot (radiant heat) threshold value (Same for thermal (radiant heat) the threshold for paw of the paw withdrawal of identical group withdrawal).Arrow instruction cutoff value (cutoff), maximum efficiency time point is shown unresponsive to most strong stimulation dynamic Thing number.(*=p<0.05, each group n=6).

Fig. 4 adjacent to sciatic nerve injection QX-314 and then injection of capsaicin anaesthetized the hind leg of animal to noxious mechanical and Thermostimulation (reaction) is without producing any movement defect.(a) sciatic nerve is only injected QX-314 (0.2%, 100 μ L), Only injection of capsaicin (0.5 μ g/ μ L, 100 μ L) or before injection of capsaicin 10 minutes injection QX-314 after, in response to increase The paw withdrawal mechanical threshold of the von Frey silks of intensity.Maximum efficiency time point is shown peak (57g, arrow) should not The animal numbers answered.(*=p<0.05, * *=p<0.01, each group n=6).(b) the paw withdrawal heat (radiation of group identical with (a) Heat) threshold value.(c) sciatic nerve injection lidocaine (2%；0.2%), QX-314 (0.2%), capsaicine (5 μ g/10 μ L) and note Motor function change (the scoring evaluated is penetrated after QX-314 and then injection of capsaicin：2=complete paralysis；1=partial paralysises；0= Do not damage).The animal numbers influenceed by injection are shown on each post.

Voltage clamp (Voltage clamp) record of sodium channel current in dorsal root ganglion neurons small Fig. 5.Data Illustrate, single eugenol has appropriate inhibition (10-20% suppression) to sodium current.Eugenol and QX-314 is co-administered Produce progressivity to block, can complete after 7 minutes.Two examples are shown, it represents 10 similar experiments of result.

TRPA activators mustard oil (MO) (50 μM) and QX-314 (5mM) is co-administered in Fig. 6.Single MO makes sodium current Reduce 20-30%, about reach plateau (plateau) after 3 minutes.MO and QX-314 is co-administered and significantly reduces sodium electricity Stream.

Embodiment

At present exploitation treatment pain medicine in the voltage-dependent channel in sensation of pain neuron very It is interested.Block sensation of pain neuron in voltage gated sodium channel can by hinder action potential starting and transmission come Pain signal is blocked, blocks calcium channel to prevent the two level (the second order) in pain signal neurotransmission to spinal cord Neuron.So far, it is to put on target outside these molecules that design, which blocks the limitation of the small organic molecule of sodium channel or calcium channel, Must be active during cell.The molecule overwhelming majority that these are outside to apply is hydrophobic and may pass through film.Therefore, they will enter Enter all cells and therefore without only influence this selectivity of sensation of pain neuron.It is well known, however, that some blocking agents, such as QX-314, it is only effective when being present in intracellular.So far, mainly with electrophysiology recording technique (such as by with machinery The whole-cell patchclamp technology that mode ruptures film and allows cell interior to dialyse) study such blocking agent.Mechanical disruption Development is eliminated to possible without the difficulty for killing cell and the difficulty that blocking agent invertibity is subsequently put on to cell interior The high throughput screening assay (possibility) of the drug molecule to play a role in the cell.

We have found the inhibitor of voltage-gated ion channel is delivered into the method into nociception neuron. By providing the means into nociception neuron for these inhibitor, the present invention allows the use in screening and treatment to exist Cell interior it is active be used as drugs block agent, but need not permeable membrane all types of molecules.In addition, limit such blocking Agent is only entered in the sensation of pain neuron under treatment situation, it is allowed to which use may not be (relative to sensation of pain neuron In other kinds of cell) in ion channel there is solid selective medicine, but by allowing these blocking agents relative Other cells in nerve and cardiovascular system preferentially enter sensation of pain neuron, to obtain to sensation of pain neuron Selectively acting.Further, since particularly TRPV1 acceptors are often active in the organization factorses related to pain (such as inflammation) It is bigger, therefore be more beneficial for entering in the specific sensation neuron mostly concerned with algesiogenic tissue.At the beginning of gargalesthesia sensitiveness Level sensory neuron also expresses TRP passages, particularly TRPV1, is also adapted to this method.

The present invention is described in greater detail below.

The inhibitor of voltage-gated ion channel

It is suitable for the inhibitor of the voltage-gated ion channel of method of the invention, composition and kit ideally It is positively charged hydrophilic compounds.In a kind of embodiment, the compound is permanent powered (that is, the electricity carried Lotus is not instantaneous).In another embodiment, the compound is instantaneous powered.Voltage gated sodium channels it is suitable Inhibitor includes but is not limited to QX-314, QX-222 (QX-222), N- octyl groups-guanidine, 9-aminoacridine and dissolves storehouse bromine Ammonium.The suitable inhibitors of voltage-gated calcium channel include but is not limited to D-890 (season methoxyverapamil) and CERM 11888 (season bepridil).

In addition, have a variety of sizes be applied to the inventive method (e.g., from about 100-4,000Da, 100-3,000Da, 100-2, 000Da, 150-1,500Da or even 200-1,200Da) and with amine groups or can be modified with the voltage with amine groups The known inhibitor of gated ion channel, the amine groups are easily modified and electrically charged (such as the quaternary amine of positively charged, or wink When powered guanylation compound).Such inhibitor include but is not limited to Riluzole, mexiletine, phenytoinum naticum, carbamazepine, Procaine, tocainide, prilocaine, norpace (disopyramide), Bencyclane, quinindium, bretylium tosylate, Lifarizine, Lamotrigine, fluorine Cinnarizine, Articaine, Bupivacaine, mepivacaine and fluspirilene.

Include the compound such as following formula I-X available for the compound in the present composition, kit and method.

In Formulas I, R^1A、R^1BAnd R^1CIt is each independently selected from H, halogen, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, OR^1H、 NR^1IR^1J、NR^1KC(O)R^1L、S(O)R^1M、SO₂R^1NR^1O、SO₂NR^1PR^1Q、SO₃R^1R、CO₂R^1S、C(O)R^1TWith C (O) NR^1UR^1V；R^1H、 R^1I、R^1J、R^1K、R^1L、R^1M、R^1N、R^1O、R^1P、R^1Q、R^1R、R^1S、R^1T、R^1UAnd R^1VIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkene Base, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；X¹Selected from-CR^1WR^1X-、-NR^1YC(O)-、-OC(O)-、-SC(O)-、-C(O)NR^1Z-、- CO₂- and-OC (S)-；R^1W、R^1X、R^1YAnd R^1ZIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkane Base；R^1DSelected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^1E、R^1FAnd R^1GIt is each independently selected from C_1–4Alkane Base, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Or R^1DAnd R^1GThe heterocycle with least one nitrogen-atoms is formed together.It is preferred that In embodiment, X¹Be-NHC (O)-.Exemplary compound of formula I includes the quaternary ammonium derivative that methylates of arcotic, such as N- Methyllidocaine, N, N- dimethyl propylamines cacaine, N, N, N- trimethyls tocainide, N- methyl Etidocaine, N- methyl sieve piperazines Cacaine, N- methyl Bupivacaine, N- methyl levobupivacaine (levobupivacaine), N- methyl mepivacaines.It can be used The method similar with method described in scheme 1 prepares these derivatives.Compound of formula I includes QX-314 (CAS 21306-56-9) With QX-222 (CAS 21236-55-5) (as follows).

In Formula II, R^2A、R^2BAnd R^2CIt is each independently selected from H, halogen, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, OR^2I、 NR^2JR^2K、NR^2LC(O)R^2M、S(O)R^2N、SO₂R^2OR^2P、SO₂NR^2QR^2R、SO₃R^2S、CO₂R^2T、C(O)R^2UWith C (O) NR^2VR^2W；R^2I、 R^2J、R^2K、R^2L、R^2M、R^2N、R^2O、R^2P、R^2Q、R^2R、R^2S、R^2T、R^2U、R^2V、R^2WIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkene Base, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；X²Selected from-CR^2XR^2Y-、-NR^2ZC(O)-、-OC(O)-、-SC(O)-、-C(O)NR^2AA-、- CO₂- and-OC (S)-；R^2X、R^2Y、R^2ZAnd R^2AAIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkane Base；R^2DSelected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^2EIt is H or C_1–4Alkyl；R^2F、R^2GAnd R^2HEach Independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Or R^2FAnd R^2GBeing formed together has two nitrogen originals The heterocycle of son.Work as R^2FAnd R^2GWhen forming the heterocycle with two nitrogen-atoms, the guanidine radicals of gained is ideally selected from

Wherein R^2HIt is H or CH₃.It is desirable that R^2FAnd R^2GThe alkylidene or alkenylene of 2-4 carbon atom are combined to form, such as 5th, the loop system of 6 and 7- yuan of rings.In preferred embodiment, X²Be-NHC (O)-.Exemplary Formula II compound includes arcotic N- guanidine derivatives (such as-C (NH) NH₂Derivative), for example, de- ethyl (desethyl)-N- guanidine radicals lidocaine, N- guanidines Base prilocaine, N- guanidine radicals tocainide, de- ethyl-N- guanidine radicals Etidocaine, debutylize (desbutyl)-N- guanidine radicals sieve piperazine cards Cause, debutylize-N- guanidine radicals Bupivacaine, debutylize-N- guanidine radicals levobupivacaine, demethylation (desmethyl)-N- guanidine radicals first Piperazine cacaine.The method similar with method described in scheme 2-5 can be used to prepare these derivatives.

Guanidine derivative (such as Formula II compound) described herein exists in the form of its uncharged alkali.These chemical combination Thing can be used as salt (that is, acid-addition salts) to apply, or (protonated through original position in the form of its uncharged alkali and form live part) Using.

The synthesis description of the parent drug of Formulas I and Formula II is in the literature.See, e.g. United States Patent (USP) No.2,441,498 (synthesis of lidocaine), United States Patent (USP) No.3,160,662 (synthesis of prilocaine), Deutsche Bundespatent No.2235745 (appropriate cards The synthesis of Buddhist nun), Deutsche Bundespatent No.2162744 (synthesis of Etidocaine), the PCT Publication WO85/00599 (conjunctions of Ropivacaine Into), United States Patent (USP) No.2,955,111 (synthesis of Bupivacaine and levobupivacaine) and United States Patent (USP) No.2,799,679 (synthesis of mepivacaine).

In formula III, n=0-3, m=0-3, and (n+m)=0-6；R^3A、R^3BAnd R^3CIt is each independently selected from H, halogen, C_1–4 Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, OR^3L、NR^3MR^3N、NR^3OC(O)R^3P、S(O)R^3Q、SO₂R^3RR^3S、 SO₂NR^3TR^3U、SO₃R^3V、CO₂R^3W、C(O)R^3XWith C (O) NR^3YR^3Z；R^3L、R^3M、R^3N、R^3O、R^3P、R^3Q、R^3R、R^3S、R^3T、R^3U、R^3V、 R^3W、R^3X、R^3Y、R^3ZIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Y³Selected from- CR^3AAR^3AB-、-NR^3ACC(O)-、-OC(O)-、-SC(O)-、-C(O)NR^3AD-、-CO₂- and-OC (S)-；R^3AA、R^3AB、R^3ACWith R^3ADIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^3D、R^3E、R^3FAnd R^3GIndependently of one another Selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl and C_3–10Alkane Heterocyclic radical；R^3H、R^3JAnd R^3KIt is each independently selected from C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl.Season in formula III Nitrogen is identified as N' herein.Exemplary formula III compound includes the quaternary ammonium derivative that methylates of arcotic, such as N '-methyl Procaine, N '-methyl proparacaine, N '-methyl allocain (allocain), N '-methyl Encainide (encainide), N '-methyl procainamide, N '-methyl methoxy Emetisan, N '-methyl Stovaine (stovaine), N '-methyl propoxycaine (propoxycaine), N '-methyl chloroprocanine, N ', N '-dimethyl Flecainide (flecainide) and N '-methyl fourth card Cause.The method similar with method described in scheme 1 can be used to prepare these derivatives.

In formula IV, n=0-3, m=0-3, and (n+m)=0-6；R^4AAnd R^4BIt is each independently selected from H, halogen, C_1–4Alkane Base, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, OR^4L、NR^4MR^4N、NR^4OC(O)R^4P、S(O)R^4Q、SO₂R^4RR^4S、SO₂NR^4TR^4U、 SO₃R^4V、CO₂R^4W、C(O)R^4XWith C (O) NR^4YR^4Z；R^4L、R^4MR^4N、R^4O、R^4P、R^4Q、R^4R、R^4S、R^4T、R^4U、R^4V、R^4W、R^4X、R^4Y And R^4ZIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Y⁴Selected from-CR^4AAR^4AB-、-NR^4ACC (O)-、-OC(O)-、-SC(O)-、-C(O)NR^4AD-、-CO₂- and-OC (S)-；R^4AA、R^4AB、R^4ACAnd R^4ADIt is each independently selected from H、C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^4C、R^4D、R^4EAnd R^4FIt is each independently selected from H, C_1–4Alkyl, C_2–4 Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl and C_3–10Alkane heterocyclic radical；X⁴Selected from H, C_1–4 Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and NR^4JR^4K；R^4JAnd R^4KIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^4G、R^4HAnd R^4IIt is each independently selected from C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl.In formula IV Quaternary nitrogen is identified as N " herein.Exemplary formula III compound includes the quaternary ammonium derivative that methylates of arcotic, such as N ", N ", N "-trimethyl procaine, N ", N ", N "-trimethyl proparacaine, N ", N ", N "-trimethyl procainamide, N ", N ", N "-trimethyl Metoclopramide, N ", N ", N "-trimethyl propoxycaine, N ", N ", N "-trimethyl chloroprocanine, N ", N "- Dimethyl butyrate cacaine, N ", N ", N "-trimethyl benzocainum and N ", N ", N "-trimethyl butamben.In usable and scheme 1 The similar method of methods described prepares these derivatives.

In Formula V, n=0-3, m=0-3, and (n+m)=0-6；R^5A、R^5BAnd R^5CIt is each independently selected from H, halogen, C_1–4Alkane Base, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, OR^5M、NR^5NR^5O、NR^5PC(O)R^5Q、S(O)R^5R、SO₂R^5SR^5T、SO₂NR^5UR^5V、 SO₃R^5W、CO₂R^5X、C(O)R^5YWith C (O) NR^5ZR^5AA；R^5M、R^5N、R^5O、R^5P、R^5Q、R^5R、R^5S、R^5T、R^5U、R^5V、R^5W、R^5X、R^5Y、R^5Z And R^5AAIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Y⁵Selected from-CR^5ABR^5AC-、- NR^5ADC(O)-、-OC(O)-、-SC(O)-、-C(O)NR^5AE-、-CO₂- and-OC (S)-；R^5AB、R^5AC、R^5ADAnd R^5AEIt is each independent Ground is selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^5D、R^5E、R^5FAnd R^5GIt is each independently selected from H, C_1–4Alkane Base, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl and C_3–10Alkane heterocyclic radical；R^5HIt is H Or C_1–4Alkyl；R^5J、R^5KAnd R^5LIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Or R^5JWith R^5KThe heterocycle with two nitrogen-atoms is formed together.Work as R^5JAnd R^5KWhen forming the heterocycle with two nitrogen-atoms, the guanidine radicals of gained Ideally it is selected from

Wherein R^5LIt is H or CH₃.It is desirable that R^5JAnd R^5KThe alkylidene or alkenylene of 2-4 carbon atom are combined to form, such as 5th, the loop system of 6 and 7- yuan of rings.Guanylation (guanylated) nitrogen in Formula V is identified as N' herein.Exemplary Formula V N- guanidine derivatives (such as-C (NH) NH of compound including arcotic₂Derivative), for example, de- ethyl-N '-guanidine radicals Proca Cause, de- ethyl-N '-guanidine radicals proparacaine, de- ethyl-N '-guanidine radicals allocain, demethylation-N '-guanidine radicals Encainide, de- ethyl- N '-guanidine radicals procainamide, de- ethyl-N '-guanidine radicals Metoclopramide, demethylation-N '-guanidine radicals stovaine, de- ethyl-N '- Guanidine radicals propoxycaine, de- ethyl-N '-guanidine radicals chloroprocanine, N '-guanidine radicals Flecainide and de- ethyl-N '-guanidine radicals totokaine.Can These derivatives are prepared using the method similar with method described in scheme 2-5.

In VI, n=0-3, m=0-3, and (n+m)=0-6；R^6AAnd R^6BIt is each independently selected from H, halogen, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, OR^6K、NR^6LR^6M、NR^6NC(O)R^6O、S(O)R^6P、SO₂R^6QR^6R、SO₂NR^6SR^6T、 SO₃R^6U、CO₂R^6V、C(O)R^6WWith C (O) NR^6XR^6Y；R^6K、R^6L、R^6M、R^6N、R^6O、R^6P、R^6Q、R^6R、R^6S、R^6T、R^6U、R^6V、R^6W、R^6X And R^6YIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Y⁶Selected from-CR^6ZR^6AA-、-NR^6ABC (O)-、-OC(O)-、-SC(O)-、-C(O)NR^6AC-、-CO₂- and-OC (S)-；R^6Z、R^6AA、R^6ABAnd R^6ACIt is each independently selected from H、C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^6C、R^6D、R^6EAnd R^6FIt is each independently selected from H, C_1–4Alkyl, C_2–4 Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl and C_3–10Alkane heterocyclic radical；X⁶Selected from H, C_1–4 Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and NR^6ADR6^AE；R^6ADAnd R^6AEIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl And C_2–4Miscellaneous alkyl；R^6GIt is H or C_1–4Alkyl；R^6H、R^6IAnd R^6JIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl And C_2–4Miscellaneous alkyl；Or R^6HAnd R^6IThe heterocycle with two nitrogen-atoms is formed together.Work as R^6HAnd R^6IFormation has two nitrogen-atoms Heterocycle when, the guanidine radicals of gained is ideally selected from

Wherein R^6JIt is H or CH₃.It is desirable that R^6HAnd R^6IThe alkylidene or alkenylene of 2-4 carbon atom are combined to form, such as 5th, the loop system of 6 and 7- yuan of rings.Guanylation nitrogen in Formula V is identified as N " herein.Exemplary Formula IV compound includes fiber crops N- guanidine derivatives (such as-C (NH) NH of liquor-saturated medicine₂Derivative), for example, N "-guanidine radicals procaine, N "-guanidine radicals proparacaine, N "-guanidine radicals procainamide, N "-guanidine radicals Metoclopramide, N "-guanidine radicals propoxycaine, N "-guanidine radicals chloroprocanine, N "-guanidine radicals Totokaine, N "-guanidine radicals benzocainum and N "-guanidine radicals butamben.The method system similar with method described in scheme 2-5 can be used These standby derivatives.

The synthesis description of formula III-VI parent drug is in the literature.It is (general see, e.g., United States Patent (USP) No.812,554 The synthesis of Shandong cacaine), Clinton etc., J.Am.Chem.Soc.74:592 (1952) (synthesis of proparacaine), United States Patent (USP) No.2,689,248 (synthesis of propoxycaine), Hadicke etc., Pharm.Zentralh.94:384 (1955) (chloroprocanines Synthesis), United States Patent (USP) No.1,889,645 (synthesis of totokaine), Salkowski etc., Ber.28:(benzene is helped for 1921 (1895) The synthesis of cacaine), Brill etc., J.Am.Chem.Soc.43:1322 (1921) (synthesis of butamben), United States Patent (USP) No.3, 931,195 (synthesis of Encainide), Yamazaki etc., J.Pharm.Soc.Japan 73:294 (1953) be (procainamide Synthesis), United States Patent (USP) No.3,177,252 (synthesis of Metoclopramide), the United States Patent (USP) No.3,900,481 (conjunctions of Flecainide Into) and Fourneau etc., Bull.Sci.Pharmacol.35:273 (1928) (synthesis of Stovaine).

In Formula VII, n=0-3, m=0-3, and (n+m)=0-6；R^7A、R^7BAnd R^7CIt is each independently selected from H, halogen, C_1–4 Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, OR^7L、NR^7MR^7N、NR^7OC(O)R^7P、S(O)R^7Q、SO₂R^7RR^7S、 SO₂NR^7TR^7U、SO₃R^7V、CO₂R^7W、C(O)R^7XWith C (O) NR^7YR^7Z；R^7L、R^7M、R^7N、R^7O、R^7P、R^7Q、R^7R、R^7S、R^7T、R^7U、R^7V、 R^7W、R^7X、R^7YAnd R^7ZIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；X⁷Selected from- CR^7AAR^7AB-、-NR^7ACC(O)-、-OC(O)-、-SC(O)-、-C(O)NR^7AD-、-CO₂- and-OC (S)-；R^7AA、R^7AB、R^7ACWith R^7ADIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^7D、R^7E、R^7FAnd R^7GIndependently of one another Selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl and C_3–10Alkane Heterocyclic radical；R^7H、R^7JAnd R^7KIt is each independently selected from C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl.The side of being preferable to carry out In formula, X⁷It is-C (O) NH-.Exemplary Formula VII compound includes the quaternary ammonium derivative that methylates of arcotic, such as N'- methyl Cinchocaine (dibucaine).The method similar with method described in scheme 1 can be used to prepare these derivatives.

In Formula VIII, n=0-3, m=0-3, and (n+m)=0-6；R^8A、R^8BAnd R^8CBe each independently selected from H, halogen, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, OR^8L、NR^8MR^8N、NR^8OC(O)R^8P、S(O)R^8Q、SO₂R^8RR^8S、 SO₂NR^8TR^8U、SO₃R^8V、CO₂R^8W、C(O)R^8XWith C (O) NR^8YR^8Z；R^8L、R^8M、R^8N、R^8O、R^8P、R^8Q、R^8R、R^8S、R^8T、R^8U、R^8V、 R^8W、R^8X、R^8YAnd R^8ZIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；X⁸Selected from- CR^8AAR^8AB-、-NR^8ACC(O)-、-OC(O)-、-SC(O)-、-C(O)NR^8AD-、-CO₂- and-OC (S)-；R^8AA、R^8AB、R^8ACWith R^8ADIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；R^8D、R^8E、R^8FAnd R^8GIndependently of one another Selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–4Miscellaneous alkyl, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl and C_3–10Alkane Heterocyclic radical；R^8HIt is H or C_1–4Alkyl；R^8I、R^8JAnd R^8KIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4 Miscellaneous alkyl；Or R^8IAnd R^8JThe heterocycle with two nitrogen-atoms is formed together.Work as R^8IAnd R^8JForm the heterocycle with two nitrogen-atoms When, the guanidine radicals of gained is ideally selected from

Wherein R^8KIt is H or CH₃.It is desirable that R^8IAnd R^8JThe alkylidene or alkenylene of 2-4 carbon atom are combined to form, such as 5th, the loop system of 6 and 7- yuan of rings.Guanylation nitrogen in Formula V is identified as N' herein.In preferred embodiment, X⁸It is-C (O) NH-.N- guanidine derivatives (such as-C (NH) NH of exemplary Formula VIII compound including arcotic₂Derivative), for example, it is de- Ethyl-N- guanidine radicals cinchocaines.The method similar with method described in scheme 2-5 can be used to prepare these derivatives.

In Formula IX, n=0-6；R^9A、R^9B、R^9C、R^9DAnd R^9EIt is each independently selected from H, halogen, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, OR^9I、NR^9JR^9K、NR^9LC(O)R^9M、S(O)R^9N、SO₂R^9OR^9P、SO₂NR^9QR^9R、SO₃R^9S、CO₂R^9T、C(O)R^9UAnd C (O)NR^9VR^9W；R^9I、R^9J、R^9K、R^9L、R^9M、R^9N、R^9O、R^9P、R^9Q、R^9R、R^9S、R^9T、R^9U、R^9VAnd R^9WBe each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；X⁹Selected from-CR^9XR^9Y- ,-O- ,-S- and-NR^9Z-；R^9X、R^9YAnd R^9ZRespectively From independently selected from H, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2–4Miscellaneous alkyl；Y⁹It is NR^9AANR^9ABNR^9ACOr NR^9ADZ⁹；R^9AA、 R^9ABAnd R^9ACIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl and C_2–4Alkynyl；R^9ADIt is H or C_1–4Alkyl；Z⁹It isR^9F、R^9GAnd R^9HIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl and C_2–4Alkynyl；Or R^9FAnd R^9GTogether Form the heterocycle with two nitrogen-atoms.Work as R^9FAnd R^9GWhen forming the heterocycle with two nitrogen-atoms, the guanidine radicals of gained is ideally It is selected from

Wherein R^9HIt is H or CH₃.It is desirable that R^9FAnd R^9GThe alkylidene or alkenylene of 2-4 carbon atom are combined to form, such as 5th, the loop system of 6 and 7- yuan of rings.In preferred embodiment, X⁹=-O-.Exemplary Formula IX compound includes N- guanidine derivatives (such as-C (NH) NH₂Derivative) (such as N- guanidine radicals Prozac) and the quaternary ammonium derivative that methylates (such as N, N- dimethyl fluorine Xi Ting).The method similar with method described in scheme 1-5 can be used to prepare these derivatives.

In Formula X, W₃It is O, NH, NCH₂R^10J、NC(O)CH₂R^10J、CHCH₂R^10J, C=CHR^10JOr C=CHR^10K；W₁-W₂It is S、O、OCHR^10K、SCHR^10K, N=CR^10K、CHR^10L-CHR^10KOr CR^10L=CR^10K；R^10A、R^10B、R^10C、R^10D、R^10E、R^10F、 R^10GAnd R^10HIt is each independently selected from H, OH, halogen, C_1–4Alkyl and C_2–4Miscellaneous alkyl；R^10JIt is CH₂CH₂X^10AOr CH (CH₃) CH₂X^10A；R^10LIt is H or OH；R^10KIt is H, OH or groupX^10AIt is NR^10MR^10NR^10POr NR^10QX^10C；X^10BIt is NR^10RR^10SOr NX^10C；R^10M、R^10N、R^10P、R^10RAnd R^10SIt is each independently selected from C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl and C_2-4 Miscellaneous alkyl, or R^10RAnd R^10SThe heterocycle with least one nitrogen-atoms is formed together；R^10QIt is H or C_1–4Alkyl；X^10CIt isR^10T、R^10UAnd R^10VIt is each independently selected from H, C_1–4Alkyl, C_2–4Alkenyl and C_2–4Alkynyl, or R^10TAnd R^10V The heterocycle with two nitrogen-atoms is formed together.Work as R^10TAnd R^10VWhen forming the heterocycle with two nitrogen-atoms, the guanidine radicals of gained Ideally it is selected from

Wherein R^10UIt is H or CH₃.It is desirable that R^10TAnd R^10VCombine to form the alkylidene or alkenylene of 2-4 carbon atom, example Such as 5,6 and the loop system of 7- yuan of rings.Exemplary Formula X compound includes N- guanidine derivatives (such as-C (NH) NH₂Derivative) With the quaternary ammonium derivative that methylates.The N- guanidine derivatives of Formula X include but is not limited to N- guanidine radicals amoxapine, demethylation-N- guanidine radicals Trimipramine, demethylation-N- guanidine radicals dosulepin, demethylation-N- guanidine radicals doxepin (doxepin), demethylation-N- guanidine radicals Ah's rice replace It is woods, N- guanidine radicals protriptyline, N- guanidine radicals desipramine, demethylation-N- guanidine radicals clomipramine, demethylation-N- guanidine radicals Clozapine, de- It is methyl-N- guanidine radicals loxapine, N- guanidine radicals nortriptyline, demethylation-N- guanidine radicals cyclobenzaprine, demethylation-N- guanidine radicals cyproheptadine, de- Methyl-N- guanidine radicals olopatadine (olopatadine), demethylation-N- guanidine radicals fenazil, demethylation-N- guanidine radicals alimemazines (trimeprazine), demethylation-N- guanidine radicals Chlorprothixene, demethylation-N- guanidine radicals chlorpromazine, demethylation-N- guanidine radicals propionyl horses Piperazine, demethylation-N- guanidine radicals prochlorperazine (prochlorperazine), demethylation-N- guanidine radicals tietylperazines (thiethylperazine), demethylation-N- guanidine radicals triperazine, de- ethyl-N- guanidine radicals ethacizine (ethacizine) and Demethylation-N- guanidine radicals imipramines.The quaternary ammonium derivative that methylates of Formula X includes but is not limited to N, N- dimethyl amoxapine, N- first Base trimipramine, N- methyl dosulepin, N- methyl doxepin, N- methyl amitriptyline, N, N- dimethyl protriptyline, N, N- bis- Methyl desipramine, N- methyl clomipramine, N- methyl Clozapine, N- methyl loxapine, N, N- dimethyl nortriptyline, N- first Base cyclobenzaprine, N- methyl cyproheptadine, N- methyl olopatadine, N- methyl isopropyls piperazine, N- methyl alimemazine, N- methyl chlorides are general Thioxanthene, N- methyl chlorpromazines, N- methyl propiomazine, N- methyl Moracizine (moricizine), N- methyl prochlorperazine, N- Methyl tietylperazine, N- methyl fluphenazinum (fluphenazine), N- methyl perphenazine (perphenazine), N- fluoromethanes Piperazine thioxanthene (flupenthixol), N- methyl vinyls perphenazine (acetophenazine), N- methyl trifluoros draw piperazine, N- methyl second Amine thiazine and N- methyl imipramines.The method similar with method described in scheme 1-5 can be used to prepare these derivatives.

Containing can be included as described herein by other ion channel blocking agent of guanylation or quaternized amine nitrogen but It is not limited to Orphenadrine, antergan (phenbenzamine), bepridil, Pimozide, penfluridol, flunarizine, fluorine department Must woods, Propiverine, disopyramide, methadone, Tolterodine, tridihexethyl salt, Tripelennamine (tripelennamine), mepyramine, Brompheniramine, chlorphenamine, dexchlorpheniramine, carbinoxamine, levacetylmethadol It is (levomethadyl acetate), gallopamil, Verapamil, devapamil, tiapamil, Emopamil, dyclonine, general Not cacaine (pramoxine), Lamotrigine, mibefradil, Gabapentin, amiloride (amiloride), your sulphur (diltiazem), nifedipine, Nimodipine, nitrendipine, cocaine, mexiletine, Propafenone, quinindium, former times difficult to understand card Cause, Articaine, Riluzole, Bencyclane, Lifarizine and strychnine.Other ion channel blocking agent can be through modification, to be incorporated to Suitable for quaternized or guanylation nitrogen-atoms.These ion channel blocking agent include but is not limited to Fosphenytoin, Ethotoin (ethotoin), the salt of phenytoinum naticum, carbamazepine, Oxcarbazepine, Topiramate (topiramate), Zonisamide and valproic acid.

Synthesis

The synthesis of the ion channel blocking agent of electric charge modification (charge-modified) can relate to hinder parent ion passage Alcohol, amine, ketone, sulfydryl or the carboxyl functional group of disconnected agent, joint (linker), huge group (bulky group) and/or powered Group carries out selective protection and deprotection.For example, the conventional protection group for amine includes carbamate (carbamates), Such as the tert-butyl group, benzyl, 2,2,2- trichloroethyls, 2- trimethylsilyethyls, 9- fluorenyl methyls, pi-allyl and a nitro Phenyl.Other conventional protection groups for amine include acid amides, such as formamide, acetamide, trifluoroacetamide, sulfonamide, trifluoro Methanesulfomide (trifluoromethanesulfonyl amides), trimethyl silyl ethyl sulfonamide And tert-butyl group sulfonamide (trimethylsilylethanesulfonamides).Example bag for the conventional protection group of carboxyl Include ester, such as methyl, ethyl, the tert-butyl group, 9- fluorenyl methyls, 2- (trimethyl silyl) ethoxyl methyl, benzyl, diphenyl Methyl, O- nitrobenzyls, ortho esters (ortho-esters) and halogen ester (halo-esters).Conventional guarantor for alcohols The example of shield base includes ether, for example, methyl, methoxy, methoxvethoxvmethvl, methylthiomethyl, benzyloxy first Base, THP trtrahydropyranyl, ethoxyethyl group, benzyl, 2- naphthyls (napthyl) methyl, O- nitrobenzyls, P- nitrobenzyls, P- first Oxy-benzyl, 9- phenyl xanthyl, trityl (including methoxy-trityls) and silyl ether.For the normal of sulfydryl Include many identical protection groups for being used for hydroxyl with the example of protection group.In addition, sulfydryl can using its reduction in the form of (for example, as Disulphide) or oxidised form (for example, as sulfonic acid, sulphonic acid ester or sulfonamide) protected.Protection group may be selected so as to realize Each protection group in molecule is removed without selective conditions (such as acid condition, the alkali required for removing other protection groups Property condition, be catalyzed by nucleopilic reagent, by Louis acid catalysis or hydrogenation).Add on to amine, alcohol, sulfydryl and carboxyl functional group Condition required for adding the condition required for protection group and removing these protection groups be provided in detail T.W.Green and P.G.M.Wuts, Protective Groups in Organic Synthesis (second edition), John Wiley＆Sons, 1991 And P.J.Kocienski, Protecting Groups, Georg Thieme Verlag, in 1994.

The ion channel blocking agent that electric charge is modified can be prepared with technology well known to those skilled in the art.Such as it can be used Technology described in documents below is by making the alkylation of parent ion channel blocker produce modification：J.March,Advanced Organic Chemistry:Reactions,Mechanisms and Structure,John Wiley&Sons,Inc., Page 1992,617.The synthesis code of standard can be used to realize conversion of the amino to guanidine radicals.For example, Mosher, which is described, passes through ammonia The reaction of base imino group methanesulfonic acid (aminoiminomethanesulfonic acid) and amine prepares the general side of monosubstituted guanidine Method (Kim etc., Tetrahedron Lett.29:3183(1988)).Bernatowicz, which develops one kind, makes primary amine and secondary amine bird The more easily method of nucleotide, wherein using 1H- pyrazoles -1- carbonamidines (carboxamidine) hydrochloride, 1-H- pyrazoles -1- (N, N'- are double (tertbutyloxycarbonyl)) carbonamidine or 1-H- pyrazoles -1- (N, N'- are double (benzyloxycarbonyl)) carbonamidine.These reagents and amine Reaction produces monosubstituted guanidine (referring to Bernatowicz etc., J.Org.Chem.57:2497(1992)；Bernatowicz etc., Tetrahedron Lett.34:3389(1993)).In addition, the synthesis of thiocarbamide and S- alkyl-isothiourea in substitution guanidine is shown In be useful intermediate (Poss etc., Tetrahedron Lett.33:5933(1992)).In some embodiments, guanidine is tool There is a part for the heterocycle of two nitrogen-atoms (see, for example, following structure).Loop system may include alkylidene or

The alkenylene of 2-4 carbon atom, for example, 5,6 and 7- yuan of rings loop system.Such as can by Schlama etc., J.Org.Chem.,62:Method disclosed in 4200 (1997) prepares such loop system.

The ion channel blocking agent that electric charge is modified can be prepared by the alkylation of amine nitrogen in parent compound, such as scheme 1 It is shown.

Scheme 1

Or the ion channel blocking agent that electric charge is modified can be prepared by introducing guanidine radicals.Parent compound can be with cyanamide (cynamide) (such as methyl cyanamide) reaction is reacted (such as the institute of scheme 3 (as shown in scheme 2) or with pyrazoles -1- carboxamidine derivatives Show, wherein Z is H or suitable protection groups).Or parent compound can with cyanogen bromide reaction, then with methyl chloride aluminium amine (methylchloroaluminum amide) reacts (as shown in Scheme 4).Also such as 2- (methyl mercapto) -2- imidazolines be can use Reagent prepares the derivative (scheme 5) of suitable functionalization.

Scheme 2

Scheme 3

Scheme 4

Scheme 5

Any ion channel blocking agent containing amine nitrogen atom can be modified as shown in scheme 1-5.

TRPV1 activators

Include but is not limited to activate injury sense available for the TRPV1 activators in the inventive method, composition and kit TRPV1 acceptors on receiver and any material for allowing at least one voltage-gated ion channel inhibitor to enter.Suitably TRPV1 activators include but is not limited to capsaicine, eugenol, arvanil (N- arachidonic acyl vanillas amine), arachidonic ethanol Amine, 2-APB ester (2APB), AM404, RTX, phorbol 12-phenylacetic acid ester 13- acetic acid esters 20- homovanillic acid ester (PPAHV), Olvanil (NE 19550), OLDA (N- oleoyls dopamine), N- arachidonic acid base dopamines (NADA), 6'- iodos RTX (6'-IRTX), C18N- acyl ethanol amines, LOX derivative such as 12- hydroperoxidations Arachidonic acid, inhibitor cysteine knot (ICK) peptide (vanilla toxin), pipering, MSK195 (N- [2- (3,4- dimethylbenzyls Base -3- (new pentane acyloxy) propyl group] -2- [4- (2- amino ethoxies) -3- anisyls] acetamide), JYL79 (N- [2- (3, 4- dimethyl benzyls -3- (new pentane acyloxy) propyl group]-N'- (4- hydroxyl -3- methoxybenzyls) thiocarbamide), hydroxyl-alpha-sanshool, 2- Amino ethoxy diphenyl-borinic acids ester, 10- salad oils, oleyl gingerol, oleyl salad oil and SU200 (N- (the 4- tert-butyl groups Benzyl)-N'- (4- hydroxyl -3- methoxybenzyls) thiocarbamide).

TRP1A activators

Include activation nociceptor or scabies available for the TRP1A activators in the inventive method, composition and kit TRP1A acceptors on gargalesthesia receiver and any material for allowing at least one voltage-gated ion channel inhibitor to enter.Close Suitable TRP1A activators include but is not limited to cinnamic acid, allyl isothiocyanate, diallyl disulfide, icilin, Chinese cassia tree Oil, wintergreen, caryophyllus oil, methacrylaldehyde, hydroxyl-alpha-sanshool, 2-APB ester, 4- Hydroxynonenals, Methyl p-hydroxybenzoate, mustard oil and 3'- carbamyl biphenyl -3- butylcyclohexyls carbamates (URB597).

P2X activators

Include activation nociceptor or itch available for the P2X activators in the inventive method, composition and kit P2X acceptors on receptor and any material for allowing at least one voltage-gated ion channel inhibitor to enter.Suitably P2X activators include but is not limited to 2- methyl mercaptos-ATP, 2' and 3'-O- (4- benzoylbenzoyls)-ATP and ATP5'- O- (3- thio triphosphates salt).

TRPM8 activators

Include activation nociceptor or scabies available for the TRPM8 activators in the inventive method, composition and kit TRPM8 acceptors on gargalesthesia receiver and any material for allowing at least one voltage-gated ion channel inhibitor to enter.Close Suitable TRPM8 activators include but is not limited to menthol, icilin, cineole, linalool, geraniol and laurine.

Other medicament

Method, composition and the kit of the present invention can be used for treatment pain (for example, neuropathic pain, nociception Property pain, idiopathic pain, inflammatory pain, dysfunction pain, antimigraine or operational pain) and gargalesthesia (for example, skin Illness such as atopic eczema or psoriasis, parasite and itch, the gargalesthesia of medicine initiation, anaphylaxis in fungal infection are itched Gargalesthesia in sense, metabolic gargalesthesia, cancer or liver and kidney failure).If desired, method described herein, composition and In kit, being generally used for treating other one or more medicaments of pain can be combined with the present invention.Such medicament is included but not It is limited to NSAIDs, opioid, tricyclic antidepressants antimelancholic, amine transporter inhibitor, anticonvulsive drug.If desired, at this In method, composition and kit described in text, other the one or more medicaments for being generally used for treating gargalesthesia can be with the present invention Combination.Such medicament includes local use or oral steroids and antihistamine.

Composite preparation

Any appropriate method that can be reduced by causing the pain sensation of target area gives the combination of the present invention.Voltage-gated The inhibitor (one or more) and TRPV1/TRPA1/P2X/TRPM8 receptor stimulating agents (one or more) of ion channel can be with Any suitable amount is contained in any suitable carrier mass, and its total amount is typically the 1-95 weights of composition total weight Measure %.The present composition can be provided by the formulation suitable in the following manner：Be administered orally, parenteral it is (such as intravenous Administration, intramuscular administration), rectally, percutaneous drug delivery, subcutaneous administration, local administration, cutaneous penetration, sublingual administration, intranasal give Medicine, vagina administration, intrathecal drug delivery, epidural administration or dosing eyes, or by inject, suck or with schneiderian membrane or oral mucosa Directly contact administration.

Therefore, the composition can be for example following form：Tablet, capsule, pill, powder, particle, supensoid agent, breast Liquid, solution, gel (including hydrogel), paste, ointment, creme, plaster, drencs (drenches), osmotic delivery Device, suppository, enema, injection, implant, spray or aerosol.Described group can be prepared according to conventional pharmaceutical practice Compound is (see, e.g. Remington:The Science and Practice of Pharmacy, the 20th edition, 2000, A.R.Gennaro is compiled, Lippincott Williams＆Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, J.Swarbrick and J.C.Boylan are compiled, 1988-1999, Marcel Dekker, New York).

Each compound in the combination can be prepared with various modes known in the art.For example, first medicament and Second medicament can formulated together or independent preparation.It is desirable that first medicament and second medicament are formulated together for same When give or almost while give these medicaments.

Can be using the Drug packing separately or individually prepared together as kit.Non-limitative example includes but is not limited to Accommodate such as the liquid in two kinds of pills, pill and powder, suppository and bottle, the kit two kinds of topical creams.Reagent Box can include help to give unit dose into the optional components of patient, such as rebuilding the bottle of powder type, for noting The syringe penetrated, the IV delivery systems of customization, inhalator etc..In addition, unit dose kit can be accommodated on the combination The specification of preparation and the administration of thing.

Kit can be fabricated to the unit dose being intended for single use for a patient；For being used for multiple times for specific patient Dosage (constant dosage, or the effect of wherein each compound change with the progress for the treatment of)；Or kit can accommodate be suitable to it is more The multiple dose (big packaging (" bulk packaging ") of individual patient administration).Reagent constituents can be assembled carton (cartons), In blister package (blister packs), bottle, pipe etc..

For the solid dosage forms being administered orally

Formulations for oral use includes tablet, and it contains the work mixed with nontoxic pharmaceutically acceptable excipient Property composition.These excipient can be for example, inert diluent or filler (such as sucrose and D-sorbite), lubricant, helping Flow agent and antitack agent (such as magnesium stearate, zinc stearate, stearic acid, silica, hydrogenated vegetable oil or talcum).

Two or more compounds can mix in tablet, capsule or other carriers, or can separate 's.In one example, on the first compound is contained on the inside of tablet, second compound on the outside of the tablet on, so as in the first chemical combination Most second compound is discharged before thing release.

The preparation being administered orally is alternatively arranged as chewable tablets, or is used as hard gelatin capsule (wherein active component and inert solid Diluent mixes), or provided as Perle (wherein active component mixes with water or oil medium).

Generally, when giving people, the oral dose of any compound in present invention combination is by the property depending on the compound Matter, and can be readily determined by those skilled in the art.Generally, such dosage is generally about 0.001mg-2000mg/ days, preferable Ground about 1mg-1000mg/ days, it more desirably it is about 5mg-500mg/ days.Up to the dosage of 200mg/ days is probably necessary.Give It is probably useful to give the minimum therapeutic dose needed for activation TRPV1/TRPA1/P2X/TRPM8 acceptors, and available standards technology is true The fixed dosage.

The administration of each medicine can continue -1 year 1 day to 4 times 1 time a day in present invention combination, or even sustainable Patient is lifelong.Constantly (chronic), long term administration will be needed in many cases.

Topical formulations

Also the topical vehicle of the active component containing 0.0001%-25% (w/w) or more can use to be adapted to composition In local use.

In preferred compositions, active component is preferably respectively 0.0001%-10% (w/w), more preferably 0.0005%-4% (w/w) activating agent.Creme can be applied 1-4 times daily, or apply as needed.For example, the metacortandracin for being adapted to local application Dragon, topical carrier will contain 0.01%-5% (w/w), preferably 0.01%-2% (w/w), more preferably 0.01%-1% (w/w).

When implementing method described herein, preferably by the vector administration combined containing the present invention in the uncomfortable position of object. For example, the finger that creme can be applied to object suffer from it is arthritic on hand.

Conjugate (conjugates)

If desired, medicine used in any combinations as described herein can be covalently attached to form formula (XI) idol each other Join thing.

(A)-(L)-(B) (XI)

In formula (XI), (A) is compound, and it activates the passage shape being present on nociceptor and/or pruriceptors Into (channel-forming) acceptor；(L) it is joint；(B) is compound, and it puts on one or more voltage-gateds Do not suppress described when suppressing the ion channel during inner surface of ion channel, but putting on the outer surface of the passage substantially Passage, and its can be formed when the acceptor is activated by the passage acceptor enter nociceptor or scratchiness by Device.

The conjugate of the present invention can be prodrug, and the conjugate is for example by desmoenzyme and exoenzyme (for example, acid amides Enzyme, esterase and phosphatase) cracking when, release medicine (A) and medicine (B).The conjugate of the present invention can also be designed, make it in body Inside largely keep complete, resist intracellular and exoenzyme splitting action, as long as being activated when passage forms acceptor When the conjugate can enter nociceptor or pruriceptors by these acceptors.Can be by designed joint (L) and in idol The covalent bond formed during connection thing synthesis with compound (A) and compound (B) is degraded to control inside conjugate.Ability can be used Technology known to field technique personnel prepares the conjugate.

Technology familiar to the person skilled in the art can be used to prepare conjugate.For example, G.Hermanson can be used, Method disclosed in Bioconjugate Techniques, Academic Press, Inc., 1996 prepares the conjugate.It is even The selectivity that the synthesis of connection thing can relate to medicine (A), the alcohol of joint and/or medicine (B), amine, ketone, sulfydryl or carboxyl functional group is protected Shield and deprotection.For example, the conventional protection group for amine includes carbamate, such as the tert-butyl group, benzyl, 2,2,2- tri- chloroethenes Base, 2- trimethylsilyethyls, 9- fluorenyl methyls, pi-allyl and m-nitro base.Other conventional protection groups for amine Including acid amides, such as formamide, acetamide, trifluoroacetamide, sulfonamide, trifluoro Methanesulfomide, trimethyl silyl second sulphur Acid amides and tert-butyl group sulfonamide.Example for the conventional protection group of carboxyl includes ester, such as methyl, ethyl, the tert-butyl group, 9- fluorenes Ylmethyl, 2- (trimethyl silyl) ethoxyl methyl, benzyl, diphenyl methyl, O- nitrobenzyls, ortho esters and halo Ester.Example for the conventional protection group of alcohols includes ether, such as methyl, methoxy, methoxvethoxvmethvl, methyl Sulphomethyl, benzyloxymethyl, THP trtrahydropyranyl, ethoxyethyl group, benzyl, 2- naphthyl methyls, O- nitrobenzyls, P- nitrobenzyls Base, P- methoxy-benzyls, 9- phenyl xanthyl, trityl (including methoxy-trityls) and silyl ether.For mercapto The example of the conventional protection group of base includes many identical protection groups for being used to protect hydroxyl.In addition, sulfydryl can go back original shape with it Formula (for example, as disulphide) or oxidised form (for example, as sulfonic acid, sulphonic acid ester or sulfonamide) are protected.It may be selected to protect Shield base so as to realize removing molecule in each protection group without required for removing other protection groups selective conditions (such as Acid condition, alkalescence condition, it is catalyzed by nucleopilic reagent, by Louis acid catalysis or hydrogenation).To amine, alcohol, sulfydryl and carboxylic The condition required for protection group is added in base functional group and the condition required for removing these protection groups is provided in detail T.W.Green and P.G.M.Wuts, Protective Groups in Organic Synthesis (second edition), John Wiley＆Sons, 1991 and P.J.Kocienski, Protecting Groups, Georg Thieme Verlag, 1994 In.Other synthesis details presented below.

Joint

The linker components of the invention of simplest form are the keys between compound (A) and compound (B), but joint is usual The molecular skeleton of linear, ring-type or branch is provided, the skeleton has side base (pendant groups), and compound (A) is covalent It is connected to compound (B).Therefore, by covalent manner (including with one kind or more in compound (A) and compound (B) Kind functional group forms key) compound (A) is connected to compound (B) to realize.Chemical reactivity function available for the purpose The example of group includes but is not limited to amino, hydroxyl, sulfydryl, carboxyl, carbonyl, alkyl (carbohydrate groups), vicinal diamines (vicinal diols), thioether, 2- amino alcohols, 2- amineothiots, guanidine radicals, imidazole radicals and phenolic group.

The covalent attachment of compound (A) and compound (B) can be realized with joint, the joint contains can be with compound (A) and these functional group reactionses present in compound (B) reactivity part.For example, the amido of compound (A) can be with joint Carboxyl or its activated derivatives reaction, generation connect the acid amides of the rwo.

The example for the part that can be reacted with sulfydryl includes XCH₂The alpha-halogen acetyl of CO- types (wherein X is Br, Cl or I) Based compound, it shows special reactivity to sulfydryl, but can also be used for modifying imidazole radicals, thioether, phenol and amino, such as Gurd, Methods Enzymol, 11:532 (1967) are described.N- maleimide derivatives are recognized as having selection to sulfydryl Property, but can also be additionally useful under certain condition with amino coupled.Such as 2- iminothiolanes (iminothiolane) (Traut etc., Biochemistry12:3266 (1973)) reagent, mercapto is introduced by the conversion of amino, if passed through Form disulphide bridges and connect, then it can be considered as mercapto reagent (sulfhydryl reagent).

The example for the reactivity part that can be reacted with amino includes such as alkylating agent and acylating agent.Representational alkylating agent Including：

(i) alpha-halogen acetyl compounds, it shows the spy to amino in the case of in the absence of reactive mercapto The opposite sex, it is XCH₂CO- types (wherein X is Cl, Br or I), such as Wong Biochemistry 24:5337 (1979) are described；

(ii) N- maleimide derivatives, it can be reacted by Michael-type or be made by adding to the acylated of cyclocarbonyl Reacted with (acylation by addition to the ring carbonyl group) and amino, such as Smyth etc. J.Am.Chem.Soc.82:4600 (1960) and Biochem.J.91:589 (1964) are described；

(iii) aryl halide, such as reactive nitro halogenated aromatic compound；

(iv) alkyl halide, such as McKenzie etc., J.Protein Chem.7:581 (1988) are described；

(v) aldehyde and ketone of schiff bases can be formed with amino, the adduct formed generally obtains stabilization by reducing Amine and stablize.

(vi) epoxide derivate, such as epoxychloropropane and bisoxiranes, it can be with amino, sulfydryl or phenol hydroxyl Base reacts；

(vii) s- triazines contain chlorine derivative, and it has very big reactivity to nucleophile such as amino, sulfydryl and hydroxyl；

(viii) aziridine (aziridines) based on s- triaizine compounds described in detail above, such as such as Ross, J.Adv.Cancer Res.2:1 (1954) are described, and it can be reacted by open loop and nucleophile (such as amino)；

(ix) squaric acid (squaric acid) diethylester, such as Tietze, Chem.Ber.124:1215 (1991) are described； With

(x) alpha-halogen Arrcostab, due to activation caused by ether oxygen atom, they are bigger than common alkyl halide reactivity Alkylating agent, such as Benneche, Eur.J.Med.Chem.28:463 (1993) are described.

Representational amino-reactive acylating agent includes：

(i) isocyanates and isothiocyanates, particularly aromatic derivative, it forms stable urea respectively and thiocarbamide derives Thing；

(ii) sulfonic acid chloride, by the Biopolymers such as Herzig 2:Record 349 (1964)；

(iii) acyl halide；

(iv) active ester, such as nitrobenzene base ester or n-hydroxysuccinimide base ester；

(v) acid anhydrides, such as mixing, symmetrical (symmetrical) or N- carboxylic acid anhydrides (carboxyanhydrides)；

(vi) it is used for other the useful reagents for forming amido link, such as M.Bodansky, Principles of Peptide Described in Synthesis, Springer-Verlag, 1984；

(vii) acyl azide (acylazides), for example, wherein being produced from using the preformed hydrazide derivatives of natrium nitrosum Raw azido, such as Wetz, Anal.Biochem.58:347 (1974) are described；With

(viii) imino-ester (imidoesters), react to form stable amidine with amino, for example, Hunter and Ludwig,J.Am.Chem.Soc.84:3491 (1962) are described.

Aldehyde and ketone can react to form schiff bases with amine, can advantageously be stabilized it by reductive amination.Alkoxy ammonia Base section easily produces stable alkoxyamine with ketone and aldehyde reaction, for example, Webb etc., Bioconjugate Chem.1:96 (1990) it is described.

Diazonium compound, such as diazo acid ester and diazonium can be included with the example of the reactivity part of carboxyl reaction Yl acetamide, the reaction of its high specificity produce ester group, such as Herriot, Adv.Protein Chem.3:169 (1947) institute State.Carboxyl modified reagent (such as carbodiimide) also can be used, it is carried out by forming O- acylureas and then forming amido link Reaction.

It should be understood that if desired, the functional group in compound (A) and/or compound (B) can be converted into other before the reaction Functional group, it is other reactive or selective for example to assign it.The example of method for the purpose is including the use of such as two Amine is converted into carboxyl by the reagent of carboxy acid anhydride；Use such as N- acetyl homocysteinethios lactone (N- Acetylhomocysteine thiolactone), S- acetyl group mercaptosuccinic acid anhydrides (acetylmercaptosuccinic Anhydride), the reagent of 2- imido grpups sulfane (imino-thiolane) or the succinimidyl derivative containing mercaptan will Amine is converted into mercaptan；Carboxyl is converted mercaptans to using the reagent of such as alpha-halogen acetic acid esters；Use such as aziridine or 2- bromines The reagent of ethamine converts mercaptans to amine；By converting carboxylate groups it is amine using reagent such as carbodiimide and then with diamines；Use example Such as the reagent of toluene sulfochloride, then carried out ester exchange with thiacetate and be hydrolyzed to mercaptan with sodium acetate alcohol being converted into Mercaptan.

If desired, can so-called zero-length joint used according to the invention, the joint is related to the anti-of compound (A) Answering property chemical group and the reactive chemical group of compound (B) are directly covalently attached without introducing other connecting material.

However, most generally, the joint will include two connected by being spaced base element (spacer element) Or more reactivity part (as described above).The presence of such interval base (spacer) allows bifunctional linker and compound (A) particular functional group's reaction and in compound (B), causes to form covalent bond therebetween.Reactivity part in joint Can identical (with base bifunctional linker) or different (different base bifunctional linker, or wherein exist several dissimilar (dissimilar) reactivity part, i.e., different Quito functional connector), there is provided a variety of possible reagents, the reagent can be in chemical combination Formed and be covalently attached between thing (A) and compound (B).

Interval base element in joint is generally made up of straight or branched, it may include C_1–10Alkyl, C_2–10Alkenyl, C_2–10Alkynes Base, C_2–6Heterocyclic radical, C_6–12Aryl, C_7–14Alkaryl, C_3–10Alkane heterocyclic radical or C_1–10Miscellaneous alkyl.

In some cases, joint is represented by formula (XII):

G¹-(Z¹)_o-(Y¹)_u-(Z²)_s-(R₃₀)-(Z³)_t-(Y²)_v-(Z⁴)_p–G² (XII)

In formula (XII), G¹It is key of the compound (A) between joint；G²It is the key between joint and compound (B)；Z¹、 Z²、Z³And Z⁴It is each independently selected from O, S and NR₃₁；R₃₁It is hydrogen, C_1–4Alkyl, C_2–4Alkenyl, C_2–4Alkynyl, C_2–6Heterocyclic radical, C_6–12 Aryl, C_7–14Alkaryl, C_3–10Alkane heterocyclic radical or C_1–7Miscellaneous alkyl；Y¹And Y²It is each independently selected from carbonyl, thiocarbonyl, sulphonyl Base or phosphoryl；O, p, s, t, u and v are each independently selected from 0 or 1；R₃₀It is C_1–10Alkyl, C_2–10Alkenyl, C_2–10Alkynyl, C_2–6It is miscellaneous Ring group, C_6–12Aryl, C_7–14Alkaryl, C_3–10Alkane heterocyclic radical or C_1–10Miscellaneous alkyl or connection G¹-(Z¹)_o-(Y¹)_u-(Z²)_s- with- (Z³)_t-(Y²)_v-(Z⁴)_p–G²Chemical bond.

Have and include but is not limited to diamines and glycol for preparing the example of the same base bifunctional linker of conjugate of the present invention, it Be selected from：Ethylenediamine, propane diamine and hexamethylene diamine, ethylene glycol, diethylene glycol (DEG), propane diols, BDO, 1,6- hexylene glycols, hexamethylene Glycol and polycaprolactone glycol.

Exemplary application

Method, composition and the kit of the present invention can be used for treating the pain related to any of various disease conditions, Including back and cervical pain, cancer pain, gynaecology's pain and labor pains, fibromyalgia, arthritis and other rheumatism pain Bitterly, orthopedic pain, postherpetic neuralgia and other neuropathic pains, sickle cell crisis (sickle cell crises), Interstitial cystitis, urethritis and other uropoiesis pain, toothache, headache, postoperative pain and operational pain (that is, with injection, Other medical treatment of tumour drain (draining an abcess), operation, dental procedure, ophthalmic operation, arthroscopy and use The relevant pain such as instrument, beauty treatment operation, dermatology operation, fracture fixation (setting fractures), biopsy).

Because the nociceptor mediation gargalesthesia of a subclass, method of the invention, composition and kit may further be used to The gargalesthesia of patient is treated, the patient suffers from for example following illness：Dermatitis, infection, parasite, insect bite, pregnancy, metabolism are lost Tune, liver or kidney failure, drug response, allergic reaction, eczema and cancer.

Pain and functional parameter

In order to detect effect any in the inventive method, composition or kit, Testing index can be used.For The inventive method, composition and kit simultaneously are used for detecting and musculoskeletal (musculoskeletal), immunoinflammatory and god Index through the disorderly related pain of characteristic of disease includes visual analogue scale (visual analog scale) (VAS), Likert is commented Point, classification (categorical) pain scores, description information (descriptors), Lequesne indexes, WOMAC indexes and AUSCAN indexes, these indexs are well known in the art.These indexs can be used for detection pain, gargalesthesia, function, it is stiff or its Its variable.

Visual analogue scale (VAS) provides the detection of one-dimensional quantity.VAS is generally represented using distance, for example, a secondary figure, It is decorated with line, the hash sign of regular interval (such as 10 1cm intervals) on line.Such as, in order to be sufficiently accurate it may be desired to patient passes through in selection line To be classified its pain or gargalesthesia with the most corresponding point of its pain or the sensation itched, one end of its center line corresponds to " without pain " (scoring is 0cm) or " no gargalesthesia ", the other end of line correspond to " insupportable pain " or " insupportable gargalesthesia " (scoring For 10cm).The program for obtain on patient how to undergo pain or gargalesthesia quantitative information provide it is a kind of simple and quick Method.VAS is scored and its application is described in such as United States Patent (USP) 6,709,406 and 6,432,937.

Similarly, Likert scorings provide the detection of one-dimensional quantity.Generally, Likert scorings have from low value (for example, 0, Represent no pain) arrive high level (for example, 7, represent extreme pain) discrete integer value.It is required that just patient's selection of experience pain Numerical value between low value and high level is to represent undergone pain degree.It is special that Likert scorings and its application are described in such as U.S. In profit 6,623,040 and 6,766,319.

Lequesne indexes and Western Ontario and McMaster Universities (WOMAC) osteoarthritis Index evaluates the pain of the knee of OA patient and buttocks, function and deadlock using homemade (self-administered) questionnaire Firmly.Knee and buttocks are covered in WOMAC, and a kind of Lequesne questionnaires are asked on knee, another individually Lequesne Volume is on buttocks.Because these questionnaires include more information content compared with VAS or Likert, these questionnaires are useful 's.WOMAC indexes and Lequesne index questionnaires both of which include surgical procedure (settings) (such as knee and stern in OA Portion's arthroplasty) in obtained extensive checking.Their measures characteristic does not have marked difference.

AUSCAN (Australian-Canadian's cheirarthritis) index uses effective, reliable and response (responsive) patient's self-report questionnaire.In a kind of situation, the questionnaire include three dimensions in 15 problems (pain, 5 Individual problem；It is stiff, 1 problem；And somatic function, 9 problems).AUSCAN indexes score using such as Likert or VAS.

Have for the inventive method, composition and kit and commented for detecting the index of pain including pain description information Divide (Pain Descriptor Scale) (PDS), visual analogue scale (VAS), word picture information scoring (Verbal Descriptor Scales) (VDS), digital pain intensity scoring (Numeric Pain Intensity Scale) (NPIS), Neuropathic pain scoring (Neuropathic Pain Scale) (NPS), neuropathic pain syndromes schedule (Neuropathic Pain Symptom Inventory) (NPSI), current pain schedule (Present Pain Inventory) (PPI), medical science of old people pain detection (Geriatric Pain Measure) (GPM), McGill pain questionnaires (McGill Pain Questionnaire) (MPQ), average pain intensity (description information difference scoring (Descriptor Differential Scale)), digital pain scores (NPS) overall assessment scoring (global evaluation score) (GES), brief McGill pain questionnaire (Short-Form McGill Pain Questionnaire), Minnesota are polynary Personality test table (Minnesota Multiphasic Personality Inventory), pain characteristic spectrum and multidimensional pain Schedule (Pain Profile and Multidimensional Pain Inventory), children's health questionnaire (Child Heath Questionnaire) and children's evaluation questionnaire (Child Assessment Questionnaire).

Gargalesthesia can be detected by subjectivity detection (VAS, Lickert, description information).Another method is to use vibrating sensing Device (vibration transducer) or motion sensitive meter are scratched to detect, and scratching is the objective correlative of gargalesthesia.

Screening

(simultaneously existing some passages allow to suppress voltage door for expression on nociceptor and pruriceptors for our discovery Control property ion channel compound enter target cell in) provide for identify have for treating the compound of pain and gargalesthesia Method.In one example, make nociceptor or pruriceptors and activation TRPV1, TRPA1, TRPM8 and/or P2X (2/3) One, two, or more of compound contact of acceptor.Also make same nociceptor or pruriceptors and the second chemical combination Thing contacts, and the second compound is when putting on nociceptor inner surface (for example, being passed through with complete cell patchclamp technique Micropipettor applies into the cell) suppress one or more voltage-gated ion channels, but it is described thin when putting on Do not suppress during extracellular surface (because the compound can not be across cell membrane).Nociceptor or pruriceptors intermediate ion passage Suppression will suppress cell and produce action potential and/or suppress signal transmission to two level neuron, all blocked in two kinds of situations The transmission of pain signal, therefore, the ability that second compound suppresses voltage-gated ion channel in nociceptor should Compound identification is that can be combined with activating the compound of TRPV1, TRPA1, TRPM8 and/or P2X (2/3) acceptor to treat pain Or the compound of gargalesthesia.

Following examples are intended to the explanation present invention and are not intended to limit the present invention.

Embodiment 1

We have recorded adult rat DRG neurons using intact cell voltage clamp (voltage clamp) recording technique In pass through the electric current of voltage gated sodium channel.To select nociceptor, we have recorded small (24 ± 5 μm；N=25 it is) neural Member simultaneously passes through the expression applied 1 μm of capsaicine and test TRPV1 acceptors in these neurons in (1 second) in short-term.In 25/ tested In 25 small neurons, capsaicine generates (10 ± 3 seconds) of extension inwardly electric current (Figure 1A, upper column), and as nociceptor Neuron it is consistent.By keeping the Depolarizing steps that current potential is -70mV to trigger sodium current.Individually 5mM is applied in immersion (Bath) Influences of the QX-314 to sodium current minimum (after 5 minutes apply, reducing by 3 ± 0.5%, n=25) (Figure 1A, left column；b).Individually apply Make sodium current moderate reduction with capsaicine (1 μm, 1-10 minutes) (31 ± 9% suppress (n=25)).However, QX-314 and capsicum When element is applied together, sodium current (suppressing 98 ± 0.4%, n=25) (Figure 1A, left column is almost completely eliminated；b).As expected, If the blocking of sodium current is QX-314 progressed into by TRPV1 acceptors caused by, suppress within a few minutes development and It is nearly completed after 15 minutes (Fig. 1 C).

Capsaicine and QX-314 is co-administered for test whether to suppress the ability of sodium current to the thin of expression TRPV1 acceptors Born of the same parents are selective, and we are also recorded for big DRG neurons (cell body (soma) diameter>40 μm) (Figure 1A, right column).These nerves In member, capsaicine does not trigger inside electric current (10/10).For minor diameter neuron, QX-314 is administered alone to sodium current shadow Ring minimum or no influence (after 10 minutes apply, electric current increases by 8 ± 4%, n=10).It is different from minor diameter neuron, it is peppery Green pepper element does not influence (averagely to increase by 3 ± 2%, n=10 after applying within 10 minutes on the sodium current in major diameter neuron.It is more worth It is noted that QX-314 and capsaicine, which is co-administered, influences minimum or no influence (10 on the sodium current in major diameter neuron Minute reduces by 9 ± 5%, n=10 after applying).Therefore, as expected, if QX-314 enters neuron by TRPV1 acceptors, The ability that the QX-314 and capsaicine being then co-administered suppress sodium current there is height to select the neuron for expressing TRPV1 acceptors Property.

We also have detected the QX-314 and capsaicine of co-administration using the inside and outside solution of physiology in current clamp Effect.As desired by from voltage clamp result, the co-administration of QX-314 and capsaicine inhibits minor diameter neuron Excitability, blocked the generation (Fig. 2,15/15 neuron) of action potential completely.

In next step, we have detected whether capsaicine and QX-314 combination can reduce Pain behaviour (pain in vivo behavior).As von Frey silks determine, by QX-314, individually (10 μ L 2% solution) are injected into the rear solid end of adult rat In to trigger paw withdrawal mechanical threshold do not make significant difference (p=0.33) (Fig. 3 A).As expected, single capsaicine (10 μ g/ 10 μ L) triggered it is spontaneous shrink back (in 5 minutes 40 ± 6 times shrink back), reflect that direct stimulation of the capsaicine to nociceptor is made With significantly reducing mechanical threshold (p after 15 and 30 minutes<0.05) (Fig. 3 a).In injection back 5 minutes, capsaicine and QX-314 Inject together and do not significantly change number of shrinking back (30 ± 7, p=0.24).However, this combination completely eliminated normal condition later Reduction (p=0.14,15 minute when detect) of the single capsaicine to mechanical threshold down.Moreover, capsaicine and QX-314 joint notes 60 minutes after penetrating, actually mechanical threshold increases to twice baseline value, (46 ± 5g vs.24 ± 3g, p 2 hours after injection< 0.05).In three animals, claw is even all insensitive to the von Frey silks (57g) of peak.Increased mechanical threshold lasts about 3 hours, then gradually it revert to foundation level (Fig. 3 A) by 4 hours.

Similar influence is observed in sensitiveness of the detection to normalized harmful radiation thermostimulation.Unexpectedly, 30 minutes after injection, single QX-314 briefly reduce thermal response incubation period (at 30 minutes, p<0.01；When every other Between point, p>0.05) (Fig. 3 B).As expected, single capsaicine (10 μ g/10 μ L) decreases thermal response incubation period (15 Hes 30 minutes, p<0.01) (Fig. 3 B).However, although individually QX-314 and single capsaicine add heat sensitivity, altogether Reaction of the animal to harmful thermostimulation has gradually been anaesthetized together with using QX-314 and capsaicine, so as to 2 hours after injection, has not been had There is animal to make a response the radiological hazard heat for applying 25 seconds.This effect continues 4 hours (Fig. 3 B) after injection.

Then, whether we test is co-administered capsaicine and QX-314 available for the blocking of generating region nerve, and The exercise effect (motor effects) observed during local anaesthesia is not carried out with lidocaine.According to 0 (to no effect；Normally Gait and limbs are placed), the scale of 1 (limb motion, but limbs are placed and dyskinesia) or 2 (completely losing limb motion) (scale) exercise effect is scored.2% lidocaine, which is injected, in the position very close to sciatic nerve (is used for local god Normal concentration through blocking), when detecting within 15 minutes, lower limb complete paralysis (6 in 6 animals) is caused, when detecting within 30 minutes, Completely or partially still there is (1.67 ± 0.2, p of mean motion scoring in paralysis<0.01；Fig. 4 C).In all animals, tactile thorn Completely losing for position reflection continue at least 30 minutes caused by swashing, completely extensive by 45 minutes these sensations and movement defect Multiple (Fig. 4).During paralysis, it is impossible to detection degree of being quick of perception.In the field experiment (pilot carried out with QX-314 Experiment in), it is evident that, when being applied together with capsaicine, the QX- more much lower than lidocaine concentrations can be used 314 produce effective local anaesthesia.Individually injection QX-314 (0.2%, 100 μ L) on motor function without influence (in 6 animals 6；Fig. 4 C), and mechanical threshold (p=0.7) or thermal response incubation period (p=0.66) are also had no significant effect (Fig. 4 A, 4B). Close to independent injection of capsaicin (0.5 μ g/ μ L, 100 μ L) at the nerve, after injection in 30 minutes, reduce mechanical threshold (p< And hot incubation period (p 0.05)<0.05) both (Fig. 4 A, 4B).During this, 4 displays in 6 animals, the limbs through injection are held Continuous bending (sustained flexion), cause slight damage (0.7 ± 0.2, the p of mean motion scoring to motoricity< 0.01), but the motion of knee and buttocks and position reflection do not change.The change of sensitivity and motion is construed to injure by we The reflectivity activation of receptor aixs cylinder generates lasting bending reflection.Enter ischium god for QX-314 and capsaicine is co-administered For side (para-sciatic nerve) region, we inject QX-314 first, injection of capsaicin after 10 minutes, we Idea be that QX-314 will be present in extracellular, once TRPV1 passages are activated, QX-314 can enter TRPV1 passages.It is real On border, in the ban inject QX-314 again injection of capsaicin when, to capsaicine, there is no or almost no behavior reaction, the behavior reaction Represent effective anesthesia to destructive stimulus.Mechanical threshold very significantly increases, so that all animals are to most hard von Frey Silk is without reaction (von Frey silks 57g；Vs. it is average 15.2 ± 3.4 to the paw withdrawal of stimulation before injection；p<0.01, n= 6), thermal response incubation period also dramatically increases (22.3 ± 2.3s vs.14.9 ± 0.4s, p<0.05, n=6).To mechanical stimulus Speech, it is that these change 30 after injection of capsaicin it will be evident that for thermostimulation that these, which change 15 minutes after injection of capsaicin, Minute is it will be evident that these changes continue 90 minutes (Fig. 4 A, 4B).5 in 6 animals are (average without any movement defect Motion scores 0.17 ± 0.17, p=0.34) (Fig. 4 C), position is reflected unchanged.One animal shows and individually injects capsicum The similar lasting bending observed when plain, but it is ofer short duration.

Method

Electrophysiology

The DRGs of 6-8 week old Sprague-Dawley rats is taken out, is inserted containing 1% Pen .- Strep (Sigma) in Dulbecco minimum essential mediums (Dulbecco's Minimum Essential Medium), Ran Houyong 5mg/ml clostridiopetidase As, 1mg/ml dispases (Dispase) II (Roche, Indianapolis, IN) are handled 90 minutes, are used 0.25% trypsin treatment 7 minutes, then add 2.5% trypsin inhibitor.In the presence of DNA enzymatic I inhibitor (50U) Grind cell, by 15%BSA (Sigma) centrifuge, 1ml neural basals (Neurobasal) culture medium (Sigma), 10 μM Resuspension in AraC, NGF (50ng/ml) and GDNF (2ng/ml), is coated on and is glued coated with polylysine (500 μ g/ml) and layer Even on the 35mm tissue culture dishes (Becton Dickinson) of albumen (5mg/ml), 8000-9000/ holes.Culture 37 DEG C, Cultivated in 5% carbon dioxide.Recorded after coated plate in 48 hours.It is elected to be being averaged for the small neuron of possible nociceptor Size is 23 ± 6 μm (n=50), and large neuron is 48 ± 8 μm (n=10).

Using Axopatch 200A amplifiers (amplifier) (Axon Instruments, Union City, CA) and The Patch pipettes (patch pipettes) that resistance is 1-2M Ω carry out whole-cell voltage-clamp or current clamp record.To voltage clamp For record, by using Parafilm (Parafilm) wrap up shin (shank) or with Sylgard (Dow Corning, Midland, MI shin) is applied to reduce pipette electric capacity.Cell capacitance is compensated for amplifier-chain, linear seepage electric current is subtracted with P/4 programs (Cell capacitance was compensated for using the amplifier circuitry,and linear leakage currents subtracted using a P/4procedure).Series resistance (usual 3-7M Ω, Always it is less than 10M Ω) compensation about 80%.The solution designs used in voltage-clamp recording are by blocking potassium and calcium current to separate Sodium current, and outside sodium is reduced to improve voltage clamp.Pipette solution (Pipette solution) be 110mM CsCl, 1mM CaCl₂、2mM MgCl₂, 11mM EGTA and 10mM HEPES, pH is adjusted to 7.4 with about 25mM CsOH.External solution It is 60mM NaCl, 60mM Choline Chlorides, 4mM KCl, 2mM CaCl₂、1mM MgCl₂、0.1mM CdCl₂, 15mM tetraethyl chlorine Change ammonium, 5mM 4-aminopyridines, 10mM glucose and 10mM HEPES, pH to 7.4 is adjusted with NaOH.For small liquid junction electricity Position (- 2.2mV) is not modified.

Current clamp record is carried out with the fast current pincers pattern of Axopatch 200A amplifiers.Pipette solution is 135mM Potassium gluconate (K gluconate)；2mM MgCl₂；6mM KCl；10mM HEPES；5mM Mg ATP；0.5mM Li₂GTP；(use KOH adjusts pH=7.4).External solution is 145mM NaCl；5mM KCl；1mM MgCl₂；2mM CaCl₂；10mM HEPES； 10mM glucose；(adjusting pH to 7.4 with NaOH).With -15mV liquid junction potential amendment film potential.

Use Digidata 1200A/D interfaces (Axon Instruments, Union with the softwares of pCLAMP 8.2 City, CA) produce order code (Command protocols) and by Data Digital (digitized).Voltage clamp rheometer Record filters (low pass filtered) in 2kHz low passes, and current clamp is recorded as 10kHz (- 3dB, 4 electrode Bessel's wave filters (4pole Bessel filter))。

With the multitube quick medicament delivery system specially designed from application QX-314 at neuron about 200-250 μm (5mM), capsaicine (1 μM or 500nM) or combinations thereof.Solution is completed within less than 1 second to exchange.

Behavior

For intraplantar injection, rat is set to get used to the processing and test of experimenter's progress first, experimenter does not know The treatment that road is carried out.Intraplantar injection carrier (20% ethanol, 5% polysorbas20 in salt solution, 10 μ L), capsaicine (1 μ g/ μ L), QX-314 (2%) or capsaicine and QX-314 mixture are to left back pawl, respectively with von Frey silks and radiant heat measuring machine Tool and heat sensitivity.

Injected for sciatic nerve, made animal get used to handling with 10 day time first.Inject lidocaine (0.2% or 2%, 100 μ L)；Single QX-314 (0.2%, 100 μ L)；Single capsaicine (50 μ g, in 100 μ L)；Or QX-314, so Injection of capsaicin (10 minutes be spaced) is to the sciatic nerve area below hip joint afterwards.Machinery is determined with von Frey silks and radiant heat Threshold and hot threshold.Using following scoring every 15 minutes motor functions for evaluating the leg through injection：0=does not have；1=part blocks；2 =block completely.Check, climb, walking on pole and reflected with position.When gait is normal, without visible limbs it is weak when, motion The grade of blocking is "None"；When limbs can move but dyskinesia and when can not support normal posture, move blocking etc. Level is " part blocks "；When limbs are weak and limp, passivity is stretched to limbs when, motion blocks grade as " completely block ".Experimenter All experiments are carried out in the case of unwitting.

Statistical analysis

Examine (Students t test) or unidirectional ANOVA to carry out statistical analysis with student t, then according to circumstances carry out The Nat (Dunnett ' s) that shuts out examines.For motion scores, inject the data obtained after 0.2% lidocaine and examined as Du Naite The control tested.Data are expressed as average value ± SEM.

Embodiment 2

We also show, eugenol (C₁₀H₁₂O₂), a kind of guaiacol (guaiacol), the 2- methoxies of the substitution of pi-allyl chain Base -4- (2- acrylic) phenol (active component in caryophyllus oil, the non-irritating activator of TRPV1 acceptors), passes through activation TRPV1 passages and promote QX-314 enter dorsal root ganglion neurons in.Fig. 5 shows sodium in small dorsal root ganglion neurons The voltage-clamp recording of channel current.Data illustrate that single eugenol has appropriate inhibition to sodium current, and (10-20% presses down System).Eugenol is co-administered and QX-314 produces progressivity and blocked, can complete after 7 minutes.Two examples are shown, it is As a result the representative of 10 similar experiments.As indicated above, individually outside QX-314 is not acted on, and internal QX-314 is blocked Sodium channel.Therefore, these experiments show that eugenol promotes QX-314 to enter DRGs by activating TRPV1 passages In neuron.

Embodiment 3

TRPA activators mustard oil (MO) (50 μM) and QX-314 (5mM) result is co-administered in Fig. 6 displays.Single MO Sodium current is reduced 20-30%, about reach plateau after 3 minutes.MO and QX-314 is co-administered and significantly reduces sodium electricity Stream.

Other embodiment

To the various modifications and variations of the method for the invention and system it will be apparent to those skilled in the art that and Without departing from scope and spirit of the present invention.Although the embodiment with reference to needed for specific describes the present invention, it should be appreciated that leads The present invention and be limited to these embodiments not too much.In fact, medical science, immunology, pharmacology, endocrinology are led Various changes obvious for domain or those skilled in the relevant art, to embodiment of the present invention are included in the present invention In the range of.

All publications referred in this specification by reference to including herein, such as each independent publication specifically With individually through be incorporated by reference herein as.

Claims

1. purposes of the compound in the medicine for preparing the pain for being used for treating patient, the compound put on one or more When suppressing the ion channel during inner surface of voltage-gated ion channel, but putting on the outer surface of the passage substantially The passage is not suppressed, wherein when TRPV1 acceptors are activated, the compound can enter nociception by the acceptor Device, wherein the compound is N- methyl Etidocaine, N- methyllidocaines, N, N- dimethyl propylamines cacaine, N, N, N- tri- Methyl tocainide, N- methyl Ropivacaine, N- methyl Bupivacaine, N- methyl levobupivacaine, N- methyl mepivacaine, QX-314, QX-222 or QX-222.

2. purposes as claimed in claim 1, wherein the compound is QX-314.

3. purposes as claimed in claim 1, wherein the compound is N- methyl Etidocaines.

4. purposes as claimed in claim 1, wherein the medicine pharmaceutically may be used comprising the compound and one or more The composition of the excipient of receiving.

5. purposes as claimed in claim 1, wherein the medicine is the composition for being formulated for locally being administered.